Plate,Well,Well Number,Characteristics [Organism],Term Source 1 REF,Term Source 1 Accession,Characteristics [Cell Type],Compound Name,Compound Identifier (CAS Number),Compound Molecular Weight,Compound URL,Compound Concentration (microMolar),Compound General Target Class,Compound General activity,Compound Information,Control Type,Channels,Image File Name
1.1,C8,1,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Linifanib,796967-16-3,375.41,https://pubchem.ncbi.nlm.nih.gov/compound/11485656,2.5,Protein Tyrosine Kinase,"CSF-1R,PDGFR,VEGFR","Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.e. FLT3). Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40501.nd2.tif_merged.tif
1.1,D8,2,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Axitinib,319460-85-0,386.47,https://pubchem.ncbi.nlm.nih.gov/compound/6450551,2.5,Protein Tyrosine Kinase,"c-Kit,PDGFR,VEGFR","Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40502.nd2.tif_merged.tif
1.1,E8,3,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Saracatinib,379231-04-6,542.03,https://pubchem.ncbi.nlm.nih.gov/compound/10302451,2.5,Angiogenesis,"Bcr-Abl,Src","Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40503.nd2.tif_merged.tif
1.1,F8,4,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Selumetinib,606143-52-6,457.68,https://pubchem.ncbi.nlm.nih.gov/compound/10127622,2.5,MAPK,MEK,"Selumetinib (AZD6244) is a potent, highly selective MEK1 inhibitor with IC50 of 14 nM in cell-free assays, also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40504.nd2.tif_merged.tif
1.1,G8,5,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Nintedanib,656247-17-5,539.62,https://pubchem.ncbi.nlm.nih.gov/compound/135423438,2.5,Protein Tyrosine Kinase,"FGFR,PDGFR,VEGFR","Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40505.nd2.tif_merged.tif
1.1,G9,6,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Afatinib,439081-18-2,485.94,https://pubchem.ncbi.nlm.nih.gov/compound/10184653,2.5,Protein Tyrosine Kinase,"EGFR,HER2","Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM in cell-free assays, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40506.nd2.tif_merged.tif
1.1,F9,7,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BMS-536924,468740-43-4,479.96,https://pubchem.ncbi.nlm.nih.gov/compound/135440466,2.5,Protein Tyrosine Kinase,IGF-1R,"BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2. ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40507.nd2.tif_merged.tif
1.1,E9,8,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Bosutinib,380843-75-4,530.45,https://pubchem.ncbi.nlm.nih.gov/compound/5328940,2.5,Angiogenesis,Src,"Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40508.nd2.tif_merged.tif
1.1,D9,9,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Cediranib,288383-20-0,450.51,https://pubchem.ncbi.nlm.nih.gov/compound/9933475,2.5,Protein Tyrosine Kinase,VEGFR,"Cediranib (AZD2171) is a highly potent VEGFR(KDR) inhibitor with IC50 of <1 nM, also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM, similar activity against c-Kit and PDGFRβ, 36-, 110-fold and >1000-fold selective more for VEGFR than PDGFR-α, CSF-1R and Flt3 in HUVEC cells. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40509.nd2.tif_merged.tif
1.1,D10,10,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Dovitinib,405169-16-6,392.43,https://pubchem.ncbi.nlm.nih.gov/compound/135398510,2.5,Angiogenesis,"c-Kit,FGFR,FLT3,PDGFR,VEGFR","Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2 in cell-free assays. Phase 4.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40510.nd2.tif_merged.tif
1.1,E10,11,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PD184352,212631-79-3,478.67,https://pubchem.ncbi.nlm.nih.gov/compound/6918454,2.5,MAPK,MEK,"PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40511.nd2.tif_merged.tif
1.1,F10,12,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Dasatinib,302962-49-8,488.01,https://pubchem.ncbi.nlm.nih.gov/compound/3062316,2.5,Angiogenesis,"Bcr-Abl,c-Kit,Src","Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40512.nd2.tif_merged.tif
1.1,G10,13,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Ridaforolimus,572924-54-0,990.21,https://pubchem.ncbi.nlm.nih.gov/compound/11520894,2.5,PI3K/Akt/mTOR,mTOR,"Ridaforolimus (Deforolimus, MK-8669) is a selective mTOR inhibitor with IC50 of 0.2 nM in HT-1080 cell line; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40513.nd2.tif_merged.tif
1.1,G11,14,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Gefitinib,184475-35-2,446.9,https://pubchem.ncbi.nlm.nih.gov/compound/123631,2.5,Protein Tyrosine Kinase,EGFR,"Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40514.nd2.tif_merged.tif
1.1,F11,15,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Imatinib Mesylate,220127-57-1,589.71,https://pubchem.ncbi.nlm.nih.gov/compound/123596,2.5,Protein Tyrosine Kinase,"Bcr-Abl,c-Kit,PDGFR","Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40515.nd2.tif_merged.tif
1.1,E11,16,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Lapatinib Ditosylate,388082-77-7,925.46,https://pubchem.ncbi.nlm.nih.gov/compound/9941095,2.5,Protein Tyrosine Kinase,"EGFR,HER2","Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40516.nd2.tif_merged.tif
1.1,D11,17,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Motesanib Diphosphate,857876-30-3,569.44,https://pubchem.ncbi.nlm.nih.gov/compound/16097729,2.5,Protein Tyrosine Kinase,"VEGFR,PDGFR,c-Kit","Motesanib Diphosphate (AMG-706) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more selective for VEGFR than PDGFR and Ret. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40517.nd2.tif_merged.tif
1.1,D12,18,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Nilotinib,641571-10-0,529.52,https://pubchem.ncbi.nlm.nih.gov/compound/644241,2.5,Angiogenesis,Bcr-Abl,Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40518.nd2.tif_merged.tif
1.1,E12,19,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,NVP-AEW541,475489-16-8,439.55,https://pubchem.ncbi.nlm.nih.gov/compound/11476171,2.5,Protein Tyrosine Kinase,IGF-1R,"NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity  for IGF-1R in a cell-based assay.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40519.nd2.tif_merged.tif
1.1,F12,20,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Pazopanib HCl,635702-64-6,473.98,https://pubchem.ncbi.nlm.nih.gov/compound/11525740,2.5,Protein Tyrosine Kinase,"c-Kit,PDGFR,VEGFR","Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40520.nd2.tif_merged.tif
1.1,G12,21,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PD0325901,391210-10-9,482.19,https://pubchem.ncbi.nlm.nih.gov/compound/9826528,2.5,DNA Damage,MEK,"PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40521.nd2.tif_merged.tif
1.1,G13,22,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PI-103,371935-74-9,348.36,https://pubchem.ncbi.nlm.nih.gov/compound/9884685,2.5,Neuronal Signaling,"Autophagy,DNA-PK,mTOR,PI3K","PI-103 is a multi-targeted PI3K inhibitor for p110α/β/δ/γ with IC50 of 2 nM/3 nM/3 nM/15 nM in cell-free assays, less potent to mTOR/DNA-PK with IC50 of 30 nM/23 nM.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40522.nd2.tif_merged.tif
1.1,F13,23,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Rapamycin,53123-88-9,914.18,https://pubchem.ncbi.nlm.nih.gov/compound/5284616,2.5,DNA Damage,"Autophagy,mTOR",Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40523.nd2.tif_merged.tif
1.1,E13,24,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Sorafenib Tosylate,475207-59-1,637.03,https://pubchem.ncbi.nlm.nih.gov/compound/406563,2.5,Neuronal Signaling,"PDGFR,Raf,VEGFR","Sorafenib Tosylate is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40524.nd2.tif_merged.tif
1.1,D13,25,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Sunitinib Malate,341031-54-7,532.56,https://pubchem.ncbi.nlm.nih.gov/compound/6456015,2.5,Microbiology,"c-Kit,PDGFR,VEGFR","Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40525.nd2.tif_merged.tif
1.1,D14,26,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Temsirolimus,162635-04-3,1030.29,https://pubchem.ncbi.nlm.nih.gov/compound/6918289,2.5,Neuronal Signaling,mTOR,"Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40526.nd2.tif_merged.tif
1.1,E14,27,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Tozasertib,639089-54-6,464.59,https://pubchem.ncbi.nlm.nih.gov/compound/5494449,2.5,Endocrinology & Hormones,Aurora Kinase,"Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40527.nd2.tif_merged.tif
1.1,F14,28,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Y-27632 2HCl,129830-38-2,320.26,https://pubchem.ncbi.nlm.nih.gov/compound/9901617,2.5,Others,"Autophagy,ROCK","Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40528.nd2.tif_merged.tif
1.1,G14,29,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Enzastaurin,170364-57-5,515.61,https://pubchem.ncbi.nlm.nih.gov/compound/176167,2.5,Neuronal Signaling,PKC,"Enzastaurin (LY317615) is a potent PKCβ selective inhibitor with IC50 of 6 nM in cell-free assays, 6- to 20-fold selectivity against PKCα, PKCγ and PKCε. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40529.nd2.tif_merged.tif
1.1,G15,30,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AC480,714971-09-2,567.01,https://pubchem.ncbi.nlm.nih.gov/compound/10437018,2.5,Neuronal Signaling,"EGFR,HER2","AC480 (BMS-599626) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, >100-fold to VEGFR2, c-Kit, Lck, MET etc. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40530.nd2.tif_merged.tif
1.1,F15,31,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Masitinib,790299-79-5,498.64,https://pubchem.ncbi.nlm.nih.gov/compound/10074640,2.5,Others,"c-Kit,PDGFR","Masitinib is a novel inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40531.nd2.tif_merged.tif
1.1,E15,32,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Pictilisib,957054-30-7,513.64,https://pubchem.ncbi.nlm.nih.gov/compound/17755052,2.5,Metabolism,PI3K,"Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40532.nd2.tif_merged.tif
1.1,D15,33,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SL-327,305350-87-2,335.35,https://pubchem.ncbi.nlm.nih.gov/compound/9549284,2.5,Others,MEK,"SL327 is a selective inhibitor for MEK1/2 with IC50 of 0.18 μM/ 0.22 μM, no activity towards Erk1, MKK3, MKK4, c-JUN, PKC, PKA, or CamKII;capable of transport through the blood-brain barrier.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40533.nd2.tif_merged.tif
1.1,D16,34,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Crizotinib,"877399-52-5, 877399-53-6 (acetate)",450.34,https://pubchem.ncbi.nlm.nih.gov/compound/11626560,2.5,Others,"ALK,c-Met","Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40534.nd2.tif_merged.tif
1.1,E16,35,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PHA-665752,477575-56-7,641.61,https://pubchem.ncbi.nlm.nih.gov/compound/10461815,2.5,Others,c-Met,"PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM in cell-free assays,  >50-fold selectivity for c-Met than RTKs or STKs.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40535.nd2.tif_merged.tif
1.1,F16,36,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,ZSTK474,475110-96-4,417.41,https://pubchem.ncbi.nlm.nih.gov/compound/11647372,2.5,Neuronal Signaling,PI3K,"ZSTK474 inhibits class I PI3K isoforms with IC50 of 37 nM in a cell-free assay, mostly PI3Kδ. Phase1/2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40536.nd2.tif_merged.tif
1.1,G16,37,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SB216763,280744-09-4,371.22,https://pubchem.ncbi.nlm.nih.gov/compound/176158,2.5,Others,GSK-3,SB216763 is a potent and selective GSK-3 inhibitor with IC50 of 34.3 nM for GSK-3α and equally effective at inhibiting human GSK-3β.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40537.nd2.tif_merged.tif
1.1,G17,38,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SB203580,152121-47-6,377.43,https://pubchem.ncbi.nlm.nih.gov/compound/176155,2.5,Transmembrane Transporters,p38 MAPK,"SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM. ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40538.nd2.tif_merged.tif
1.1,F17,39,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SB202190,152121-30-7,331.34,https://pubchem.ncbi.nlm.nih.gov/compound/5169,2.5,PI3K/Akt/mTOR,p38 MAPK,"SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40539.nd2.tif_merged.tif
1.1,E17,40,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,MK-2206 2HCl,1032350-13-2,480.39,https://pubchem.ncbi.nlm.nih.gov/compound/46930998,2.5,Others,Akt,"MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40540.nd2.tif_merged.tif
1.1,D17,41,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SU11274,658084-23-2,568.09,https://pubchem.ncbi.nlm.nih.gov/compound/9549297,2.5,Neuronal Signaling,c-Met,"SU11274 is a selective Met inhibitor with IC50 of 10 nM in cell-free assays, no effects on PGDFRβ, EGFR or Tie2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40541.nd2.tif_merged.tif
1.1,C17,42,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Brivanib,649735-46-6,370.38,https://pubchem.ncbi.nlm.nih.gov/compound/11234052,2.5,GPCR & G Protein,"FGFR,VEGFR","Brivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40542.nd2.tif_merged.tif
1.1,C16,43,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Refametinib,923032-37-5,572.34,https://pubchem.ncbi.nlm.nih.gov/compound/44182295,2.5,Others,MEK,"Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40543.nd2.tif_merged.tif
1.1,C15,44,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Linsitinib,867160-71-2,421.49,https://pubchem.ncbi.nlm.nih.gov/compound/11640390,2.5,Others,IGF-1R,"Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40544.nd2.tif_merged.tif
1.1,C14,45,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,KU-55933,587871-26-9,395.49,https://pubchem.ncbi.nlm.nih.gov/compound/5278396,2.5,Others,ATM/ATR,"KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40545.nd2.tif_merged.tif
1.1,C13,46,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GSK1904529A,1089283-49-7,851.96,https://pubchem.ncbi.nlm.nih.gov/compound/25124816,2.5,Others,IGF-1R,"GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40546.nd2.tif_merged.tif
1.1,C12,47,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PF-04217903,956905-27-4,372.38,https://pubchem.ncbi.nlm.nih.gov/compound/17754438,2.5,Others,c-Met,"PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM in A549 cell line, susceptible to oncogenic mutations (no activity to Y1230C mutant). Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40547.nd2.tif_merged.tif
1.1,C11,48,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,MLN8054,869363-13-3,476.86,https://pubchem.ncbi.nlm.nih.gov/compound/11712649,2.5,Others,Aurora Kinase,MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM in Sf9 insect cell. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40548.nd2.tif_merged.tif
1.1,C10,49,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40549.nd2.tif_merged.tif
1.1,C9,50,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-1_40550.nd2.tif_merged.tif
1.2,C8,1,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Vatalanib 2HCl,212141-51-0,419.73,https://pubchem.ncbi.nlm.nih.gov/compound/22386467,2.5,Others,"c-Kit,VEGFR","Vatalanib (PTK787) 2HCl is an inhibitor of VEGFR2/KDR with IC50 of 37 nM in a cell-free assay, less potent against VEGFR1/Flt-1, 18-fold against VEGFR3/Flt-4. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40501.nd2.tif_merged.tif
1.2,D8,2,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,U0126-EtOH,1173097-76-1,426.56,https://pubchem.ncbi.nlm.nih.gov/compound/16220066,2.5,Others,MEK,"U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40502.nd2.tif_merged.tif
1.2,E8,3,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,ZM 447439,331771-20-1,513.59,https://pubchem.ncbi.nlm.nih.gov/compound/9914412,2.5,Others,Aurora Kinase,"ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40503.nd2.tif_merged.tif
1.2,F8,4,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GDC-0879,905281-76-7,334.37,https://pubchem.ncbi.nlm.nih.gov/compound/11717001,2.5,Others,Raf,"GDC-0879 is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40504.nd2.tif_merged.tif
1.2,G8,5,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,LY294002,154447-36-6,307.34,https://pubchem.ncbi.nlm.nih.gov/compound/3973,2.5,Others,"Autophagy,PI3K","LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40505.nd2.tif_merged.tif
1.2,G9,6,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,OSU-03012,742112-33-0,460.45,https://pubchem.ncbi.nlm.nih.gov/compound/10027278,2.5,Others,PDK,OSU-03012 (AR-12) is a potent inhibitor of recombinant PDK-1 with IC50 of 5 μM in a cell-free assay and 2-fold increase in potency over OSU-02067.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40506.nd2.tif_merged.tif
1.2,F9,7,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Danusertib,827318-97-8,474.55,https://pubchem.ncbi.nlm.nih.gov/compound/11442891,2.5,Others,"Aurora Kinase,Bcr-Abl,c-RET,FGFR","Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40507.nd2.tif_merged.tif
1.2,E9,8,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BI 2536,755038-02-9,521.66,https://pubchem.ncbi.nlm.nih.gov/compound/11364421,2.5,Others,PLK,BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40508.nd2.tif_merged.tif
1.2,D9,9,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Foretinib,849217-64-7,632.65,https://pubchem.ncbi.nlm.nih.gov/compound/42642645,2.5,Others,"c-Met,VEGFR","Foretinib (GSK1363089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40509.nd2.tif_merged.tif
1.2,D10,10,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GSK690693,937174-76-0,425.48,https://pubchem.ncbi.nlm.nih.gov/compound/16725726,2.5,Others,Akt,"GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40510.nd2.tif_merged.tif
1.2,E10,11,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,JNJ-38877605,943540-75-8,377.35,https://pubchem.ncbi.nlm.nih.gov/compound/46911863,2.5,Others,c-Met,"JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40511.nd2.tif_merged.tif
1.2,F10,12,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Triciribine,35943-35-2,320.3,https://pubchem.ncbi.nlm.nih.gov/compound/65399,2.5,Others,Akt,"Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40512.nd2.tif_merged.tif
1.2,G10,13,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Cabozantinib,849217-68-1,501.51,https://pubchem.ncbi.nlm.nih.gov/compound/25102847,2.5,Others,"TAM Receptor,c-Kit,c-Met,FLT3,Tie-2,VEGFR","Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40513.nd2.tif_merged.tif
1.2,G11,14,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Everolimus,159351-69-6,958.22,https://pubchem.ncbi.nlm.nih.gov/compound/6442177,2.5,Others,mTOR,Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40514.nd2.tif_merged.tif
1.2,F11,15,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BMS-754807,1001350-96-4,461.49,https://pubchem.ncbi.nlm.nih.gov/compound/24785538,2.5,Others,"c-Met,IGF-1R,Trk receptor","BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40515.nd2.tif_merged.tif
1.2,E11,16,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Alisertib,1028486-01-2,518.92,https://pubchem.ncbi.nlm.nih.gov/compound/24771867,2.5,Others,Aurora Kinase,Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40516.nd2.tif_merged.tif
1.2,D11,17,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AT9283,896466-04-9,381.43,https://pubchem.ncbi.nlm.nih.gov/compound/135398495,2.5,Others,"Aurora Kinase,Bcr-Abl,JAK","AT9283 is a potent JAK2/3 inhibitor with IC50 of 1.2 nM/1.1 nM in cell-free assays; also potent to Aurora A/B, Abl(T315I). Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40517.nd2.tif_merged.tif
1.2,D12,18,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Brivanib Alaninate,649735-63-7,441.46,https://pubchem.ncbi.nlm.nih.gov/compound/11154925,2.5,Others,"FGFR,VEGFR","Brivanib alaninate (BMS-582664) is the prodrug of BMS-540215, an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40518.nd2.tif_merged.tif
1.2,E12,19,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Tyrphostin B42,133550-30-8,294.3,https://pubchem.ncbi.nlm.nih.gov/compound/5328779,2.5,Others,"EGFR,JAK","Tyrphostin B42 (AG-490) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40519.nd2.tif_merged.tif
1.2,F12,20,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SNS-032,345627-80-7,380.53,https://pubchem.ncbi.nlm.nih.gov/compound/3025986,2.5,Others,CDK,"SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40520.nd2.tif_merged.tif
1.2,G12,21,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Barasertib,722544-51-6,507.56,https://pubchem.ncbi.nlm.nih.gov/compound/16007391,2.5,Others,Aurora Kinase,"Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40521.nd2.tif_merged.tif
1.2,G13,22,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PLX-4720,918505-84-7,413.83,https://pubchem.ncbi.nlm.nih.gov/compound/24180719,2.5,Others,Raf,"PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40522.nd2.tif_merged.tif
1.2,F13,23,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Roscovitine,186692-46-6,354.45,https://pubchem.ncbi.nlm.nih.gov/compound/160355,2.5,Others,CDK,"Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40523.nd2.tif_merged.tif
1.2,E13,24,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SNS-314 Mesylate,1146618-41-8,527.04,https://pubchem.ncbi.nlm.nih.gov/compound/24995523,2.5,Others,Aurora Kinase,"SNS-314 Mesylate is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively. It is less potent to Trk A/B, Flt4, Fms, Axl, c-Raf and DDR2. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40524.nd2.tif_merged.tif
1.2,D13,25,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Lenvatinib,417716-92-8,426.85,https://pubchem.ncbi.nlm.nih.gov/compound/9823820,2.5,Protein Tyrosine Kinase,VEGFR,"Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in cell-free assays. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40525.nd2.tif_merged.tif
1.2,D14,26,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CP-724714,537705-08-1,469.53,https://pubchem.ncbi.nlm.nih.gov/compound/57345837,2.5,Protein Tyrosine Kinase,"EGFR,HER2","CP-724714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM, >640-fold selectivity against EGFR, InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met etc in cell-free assays. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40526.nd2.tif_merged.tif
1.2,E14,27,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,TGX-221,663619-89-4,364.44,https://pubchem.ncbi.nlm.nih.gov/compound/9907093,2.5,PI3K/Akt/mTOR,PI3K,"TGX-221 is a p110β-specific inhibitor with IC50 of 5 nM in a cell-free assay, 1000-fold more selective for p110β than p110α.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40527.nd2.tif_merged.tif
1.2,F14,28,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,WZ3146,1214265-56-1,464.95,https://pubchem.ncbi.nlm.nih.gov/compound/44607360,2.5,Protein Tyrosine Kinase,EGFR,WZ3146 is a mutant-selective irreversible inhibitor of EGFR(L858R) and EGFR(E746_A750) with IC50 of 2 nM and 2 nM; does not inhibit ERBB2 phosphorylation (T798I).,,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40528.nd2.tif_merged.tif
1.2,G14,29,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CYC116,693228-63-6,368.46,https://pubchem.ncbi.nlm.nih.gov/compound/6420138,2.5,Cell Cycle,"Aurora Kinase,VEGFR","CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM, is less potent to VEGFR2 (Ki of 44 nM), with 50-fold greater potency than CDKs, not active against PKA, Akt/PKB, PKC, no effect on GSK-3α/β, CK2, Plk1 and SAPK2A. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40529.nd2.tif_merged.tif
1.2,G15,30,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,WZ4002,1213269-23-8,494.18,https://pubchem.ncbi.nlm.nih.gov/compound/44607530,2.5,Protein Tyrosine Kinase,EGFR,"WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM in BaF3 cell line; does not inhibit ERBB2 phosphorylation (T798I).",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40530.nd2.tif_merged.tif
1.2,F15,31,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PD98059,167869-21-8,267.28,https://pubchem.ncbi.nlm.nih.gov/compound/4713,2.5,MAPK,MEK,"PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40531.nd2.tif_merged.tif
1.2,E15,32,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Regorafenib,755037-03-7,482.82,https://pubchem.ncbi.nlm.nih.gov/compound/11167602,2.5,Protein Tyrosine Kinase,"c-RET,VEGFR","Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40532.nd2.tif_merged.tif
1.2,D15,33,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,WZ8040,1214265-57-2,481.01,https://pubchem.ncbi.nlm.nih.gov/compound/44607531,2.5,Protein Tyrosine Kinase,EGFR,"WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor, does not inhibit ERBB2 phosphorylation (T798I).",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40533.nd2.tif_merged.tif
1.2,D16,34,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,ENMD-2076,934353-76-1,375.47,https://pubchem.ncbi.nlm.nih.gov/compound/16041424,2.5,Angiogenesis,"Aurora Kinase,FLT3,VEGFR","ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40534.nd2.tif_merged.tif
1.2,E16,35,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CUDC-101,1012054-59-9,434.49,https://pubchem.ncbi.nlm.nih.gov/compound/24756910,2.5,Epigenetics,"EGFR,HDAC,HER2","CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40535.nd2.tif_merged.tif
1.2,F16,36,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Tivozanib,475108-18-0,454.86,https://pubchem.ncbi.nlm.nih.gov/compound/9911830,2.5,Protein Tyrosine Kinase,"c-Kit,PDGFR,VEGFR","Tivozanib (AV-951) is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 30 nM/6.5 nM/15 nM, and also inhibits PDGFR and c-Kit, low activity observed against FGFR-1, Flt3, c-Met, EGFR and IGF-1R. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40536.nd2.tif_merged.tif
1.2,G16,37,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,YM201636,371942-69-7,467.48,https://pubchem.ncbi.nlm.nih.gov/compound/9956222,2.5,PI3K/Akt/mTOR,PI3K,"YM201636 is a selective PIKfyve inhibitor with IC50 of 33 nM, less potent to p110α and insensitive to Fabl (yeast orthologue).",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40537.nd2.tif_merged.tif
1.2,G17,38,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,OSI-930,728033-96-3,443.44,https://pubchem.ncbi.nlm.nih.gov/compound/9868037,2.5,Protein Tyrosine Kinase,"c-Kit,CSF-1R,VEGFR","OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC50 of 80 nM, 9 nM and 15 nM, respectively; also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β, Flt-3 and Abl. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40538.nd2.tif_merged.tif
1.2,F17,39,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,KU-0063794,938440-64-3,465.54,https://pubchem.ncbi.nlm.nih.gov/compound/16736978,2.5,PI3K/Akt/mTOR,mTOR,KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40539.nd2.tif_merged.tif
1.2,E17,40,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Flavopiridol,146426-40-6,401.84,https://pubchem.ncbi.nlm.nih.gov/compound/5287969,2.5,Cell Cycle,CDK,"Flavopiridol (Alvocidib) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM. It is 7.5-fold more selective for CDK1, 2, 4, 6 versus CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40540.nd2.tif_merged.tif
1.2,D17,41,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AG-1024,65678-07-1,305.17,https://pubchem.ncbi.nlm.nih.gov/compound/2044,2.5,Protein Tyrosine Kinase,IGF-1R,"AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40541.nd2.tif_merged.tif
1.2,C17,42,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Amuvatinib,850879-09-3,447.51,https://pubchem.ncbi.nlm.nih.gov/compound/11282283,2.5,Protein Tyrosine Kinase,"c-Kit,FLT3,PDGFR","Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40542.nd2.tif_merged.tif
1.2,C16,43,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,JNJ-7706621,443797-96-4,394.36,https://pubchem.ncbi.nlm.nih.gov/compound/5330790,2.5,Cell Cycle,"Aurora Kinase,CDK",JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6 in cell-free assays. It also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40543.nd2.tif_merged.tif
1.2,C15,44,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CHIR-99021,252917-06-9,465.34,https://pubchem.ncbi.nlm.nih.gov/compound/9956119,2.5,PI3K/Akt/mTOR,GSK-3,"CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40544.nd2.tif_merged.tif
1.2,C14,45,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PD173074,219580-11-7,523.67,https://pubchem.ncbi.nlm.nih.gov/compound/1401,2.5,Angiogenesis,"FGFR,VEGFR","PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40545.nd2.tif_merged.tif
1.2,C13,46,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,WYE-354,1062169-56-5,495.53,https://pubchem.ncbi.nlm.nih.gov/compound/44219749,2.5,PI3K/Akt/mTOR,mTOR,"WYE-354 is a potent, specific and ATP-competitive inhibitor of mTOR with IC50 of 5 nM, blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) not P-AKT(T308), selective for mTOR than PI3Kα (>100-fold) and PI3Kγ (>500-fold). ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40546.nd2.tif_merged.tif
1.2,C12,47,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Vemurafenib,918504-65-1,489.92,https://pubchem.ncbi.nlm.nih.gov/compound/42611257,2.5,MAPK,Raf,"Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM in cell-free assay.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40547.nd2.tif_merged.tif
1.2,C11,48,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BX-795,702675-74-9,591.47,https://pubchem.ncbi.nlm.nih.gov/compound/10077147,2.5,PI3K/Akt/mTOR,"IκB/IKK,PDK","BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC in cell-free assays, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40548.nd2.tif_merged.tif
1.2,C10,49,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40549.nd2.tif_merged.tif
1.2,C9,50,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-2_40550.nd2.tif_merged.tif
1.3,C8,1,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BX-912,702674-56-4,471.35,https://pubchem.ncbi.nlm.nih.gov/compound/11754511,2.5,PI3K/Akt/mTOR,PDK,"BX912 is a potent and specific PDK1 inhibitor with IC50 of 12 nM, 9- and 105- fold greater selectivity for PDK1 than PKA and PKC in cell-free assays, respectively. In comparison to GSK3β, selectivity for PDK1 is 600-fold.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40501.nd2.tif_merged.tif
1.3,D8,2,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Genistein,446-72-0,270.24,https://pubchem.ncbi.nlm.nih.gov/compound/5280961,2.5,Protein Tyrosine Kinase,"EGFR,Topoisomerase","Genistein, a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK)  which blocks the mitogenic effect mediated by EGF on NIH-3T3 cells with IC50 of 12μM or by insulin with IC50 of 19 μM. ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40502.nd2.tif_merged.tif
1.3,E8,3,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,TG100-115,677297-51-7,346.34,https://pubchem.ncbi.nlm.nih.gov/compound/10427712,2.5,PI3K/Akt/mTOR,PI3K,"TG100-115 is a PI3Kγ/δ inhibitor with IC50 of 83 nM/235 nM, with little effect on PI3Kα/β. Phase 1/2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40503.nd2.tif_merged.tif
1.3,F8,4,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,MGCD-265,875337-44-3,517.6,https://pubchem.ncbi.nlm.nih.gov/compound/24901704,2.5,Protein Tyrosine Kinase,"c-Met,Tie-2,VEGFR","MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2. Phase 1/2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40504.nd2.tif_merged.tif
1.3,G8,5,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Rigosertib,1225497-78-8,473.47,https://pubchem.ncbi.nlm.nih.gov/compound/23696523,2.5,Cell Cycle,PLK,Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40505.nd2.tif_merged.tif
1.3,G9,6,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Ki8751,228559-41-9,469.41,https://pubchem.ncbi.nlm.nih.gov/compound/11317348,2.5,Protein Tyrosine Kinase,"c-Kit,PDGFR,VEGFR","Ki8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM, >40-fold selective for VEGFR2 than c-Kit, PDGFRα and FGFR-2, little activity to EGFR, HGFR and InsR.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40506.nd2.tif_merged.tif
1.3,F9,7,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Ruxolitinib,941678-49-5,306.37,https://pubchem.ncbi.nlm.nih.gov/compound/25126798,2.5,JAK/STAT,JAK,"Ruxolitinib (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3. ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40507.nd2.tif_merged.tif
1.3,E9,8,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Pelitinib,257933-82-7,467.92,https://pubchem.ncbi.nlm.nih.gov/compound/6445562,2.5,Protein Tyrosine Kinase,EGFR,Pelitinib (EKB-569) is a potent irreversible EGFR inhibitor with IC50 of 38.5 nM. Phase2.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40508.nd2.tif_merged.tif
1.3,D9,9,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Aurora A Inhibitor I,1158838-45-9,588.07,https://pubchem.ncbi.nlm.nih.gov/compound/44139710,2.5,Cell Cycle,Aurora Kinase,"Aurora A Inhibitor I is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40509.nd2.tif_merged.tif
1.3,D10,10,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PHA-680632,398493-79-3,501.62,https://pubchem.ncbi.nlm.nih.gov/compound/11249084,2.5,Cell Cycle,Aurora Kinase,"PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGFR1, FLT3, LCK, PLK1, STLK2, and VEGFR2/3. ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40510.nd2.tif_merged.tif
1.3,E10,11,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,VX-745,209410-46-8,436.26,https://pubchem.ncbi.nlm.nih.gov/compound/3038525,2.5,MAPK,p38 MAPK,"VX-745 is a potent and selective inhibitor of p38α with IC50 of 10 nM, 22-fold greater selectivity versus p38β and no inhibition to p38γ.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40511.nd2.tif_merged.tif
1.3,F10,12,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Thiazovivin,1226056-71-8,311.36,https://pubchem.ncbi.nlm.nih.gov/compound/46209426,2.5,Cell Cycle,ROCK,"Thiazovivin is a novel ROCK inhibitor with IC50 of 0.5 μM in a cell-free assay, promotes hESC survival after single-cell dissociation.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40512.nd2.tif_merged.tif
1.3,G10,13,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SP600125,129-56-6,220.23,https://pubchem.ncbi.nlm.nih.gov/compound/8515,2.5,MAPK,JNK,"SP600125 is a broad-spectrum JNK inhibitor for JNK1, JNK2 and JNK3 with IC50 of 40 nM, 40 nM and 90 nM in cell-free assays, respectively; 10-fold greater selectivity against MKK4, 25-fold greater selectivity against MKK3, MKK6, PKB, and PKCα, and 100-fold selectivity against ERK2, p38, Chk1, EGFR etc.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40513.nd2.tif_merged.tif
1.3,G11,14,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZD6482,1173900-33-8,408.45,https://pubchem.ncbi.nlm.nih.gov/compound/44137675,2.5,PI3K/Akt/mTOR,PI3K,"AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ in cell-free assays. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40514.nd2.tif_merged.tif
1.3,F11,15,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Orantinib,252916-29-3,310.35,https://pubchem.ncbi.nlm.nih.gov/compound/5329099,2.5,Protein Tyrosine Kinase,"FGFR,PDGFR,VEGFR","Orantinib (TSU-68, SU6668) has greatest potency against PDGFR autophosphorylation with Ki of 8 nM in a cell-free assay, but also strongly inhibits Flk-1 and FGFR1 trans-phosphorylation, little activity against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2; does not inhibit EGFR. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40515.nd2.tif_merged.tif
1.3,E11,16,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GSK429286A,864082-47-3,432.37,https://pubchem.ncbi.nlm.nih.gov/compound/11373846,2.5,Cell Cycle,ROCK,"GSK429286A is a selective inhibitor of ROCK1 and ROCK2 with IC50 of 14 nM and 63 nM, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40516.nd2.tif_merged.tif
1.3,D11,17,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Pimasertib,1236699-92-5,431.2,https://pubchem.ncbi.nlm.nih.gov/compound/44187362,2.5,MAPK,MEK,"Pimasertib (AS-703026) is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2 with IC50 of 5 nM-2 μM in MM cell lines. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40517.nd2.tif_merged.tif
1.3,D12,18,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,HMN-214,173529-46-9,424.47,https://pubchem.ncbi.nlm.nih.gov/compound/9888590,2.5,Cell Cycle,PLK,"HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40518.nd2.tif_merged.tif
1.3,E12,19,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AEE788,497839-62-0,440.58,https://pubchem.ncbi.nlm.nih.gov/compound/10297043,2.5,Protein Tyrosine Kinase,"EGFR,HER2,VEGFR","AEE788 (NVP-AEE788) is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKCα and CDK1. Phase 1/2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40519.nd2.tif_merged.tif
1.3,F12,20,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PHA-793887,718630-59-2,361.48,https://pubchem.ncbi.nlm.nih.gov/compound/46191454,2.5,Cell Cycle,CDK,"PHA-793887 is a novel and potent inhibitor of CDK2, CDK5 and CDK7 with IC50 of 8 nM, 5 nM and 10 nM. It is greater than 6-fold more selective for CDK2, 5, and 7 than CDK1, 4, and 9. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40520.nd2.tif_merged.tif
1.3,G12,21,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PIK-93,593960-11-3,389.88,https://pubchem.ncbi.nlm.nih.gov/compound/6852167,2.5,PI3K/Akt/mTOR,PI3K,"PIK-93 is the first potent, synthetic PI4K (PI4KIIIβ) inhibitor with IC50 of 19 nM; shown to inhibit PI3Kα with IC50 of 39 nM.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40521.nd2.tif_merged.tif
1.3,G13,22,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Ponatinib,943319-70-8,532.56,https://pubchem.ncbi.nlm.nih.gov/compound/24826799,2.5,Angiogenesis,"Bcr-Abl,FGFR,PDGFR,VEGFR","Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40522.nd2.tif_merged.tif
1.3,F13,23,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Voxtalisib Analogue,1349796-36-6,599.66,https://pubchem.ncbi.nlm.nih.gov/compound/49867926,2.5,PI3K/Akt/mTOR,"mTOR,PI3K","Voxtalisib (SAR245409, XL765) Analogue is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40523.nd2.tif_merged.tif
1.3,E13,24,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AT7519,844442-38-2,382.24,https://pubchem.ncbi.nlm.nih.gov/compound/11338033,2.5,Cell Cycle,CDK,"AT7519 is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM. It is less potent to CDK3 and little active to CDK7. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40524.nd2.tif_merged.tif
1.3,D13,25,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Quizartinib,950769-58-1,560.67,https://pubchem.ncbi.nlm.nih.gov/compound/24889392,2.5,Angiogenesis,FLT3,"Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM in MV4-11 and RS4;11 cells, respectively, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40525.nd2.tif_merged.tif
1.3,D14,26,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Hesperadin,422513-13-1,516.65,https://pubchem.ncbi.nlm.nih.gov/compound/135421442,2.5,Cell Cycle,Aurora Kinase,"Hesperadin potently inhibits Aurora B with IC50 of 250 nM in a cell-free assay. It markedly reduces the activity of AMPK, Lck, MKK1, MAPKAP-K1, CHK1 and PHK while it does not inhibit MKK1 activity in vivo.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40526.nd2.tif_merged.tif
1.3,E14,27,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BIX 02188,1094614-84-2,412.48,https://pubchem.ncbi.nlm.nih.gov/compound/135398492,2.5,MAPK,MEK,"BIX02188 is a selective inhibitor of MEK5 with IC50 of 4.3 nM, also inhibits ERK5 catalytic activity with IC50 of 810 nM, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40527.nd2.tif_merged.tif
1.3,F14,28,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BIX 02189,1094614-85-3,440.54,https://pubchem.ncbi.nlm.nih.gov/compound/135659062,2.5,MAPK,MEK,"BIX02189 is a selective inhibitor of MEK5 with IC50 of 1.5 nM, also inhibits ERK5 catalytic activity with IC50 of 59 nM in cell-free assays, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40528.nd2.tif_merged.tif
1.3,G14,29,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZD7762,860352-01-8,362.42,https://pubchem.ncbi.nlm.nih.gov/compound/11152667,2.5,Cell Cycle,Chk,"AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM in a cell-free assay. It is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40529.nd2.tif_merged.tif
1.3,G15,30,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,R406,841290-80-0,470.45,https://pubchem.ncbi.nlm.nih.gov/compound/11213558,2.5,Angiogenesis,Syk,"R406 (free base) is a potent Syk inhibitor with IC50 of 41 nM in a cell-free assay, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40530.nd2.tif_merged.tif
1.3,F15,31,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CP-673451,343787-29-1,417.5,https://pubchem.ncbi.nlm.nih.gov/compound/10158940,2.5,Protein Tyrosine Kinase,PDGFR,"CP-673451 is a selective inhibitor of PDGFRα/β with IC50 of 10 nM/1 nM in cell-free assays, exhibits >450-fold selectivity over other angiogenic receptors, has antiangiogenic and antitumor activity.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40531.nd2.tif_merged.tif
1.3,E15,32,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZD8055,1009298-09-2,465.54,https://pubchem.ncbi.nlm.nih.gov/compound/25262965,2.5,PI3K/Akt/mTOR,mTOR,"AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40532.nd2.tif_merged.tif
1.3,D15,33,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PHT-427,1191951-57-1,409.61,https://pubchem.ncbi.nlm.nih.gov/compound/44240850,2.5,PI3K/Akt/mTOR,"Akt,PDK","PHT-427 is a dual Akt and PDPK1 inhibitor (high affinity binding for the PH domains of Akt and PDPK1) with Ki of 2.7 μM and 5.2 μM, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40533.nd2.tif_merged.tif
1.3,D16,34,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,KRN 633,286370-15-8,416.86,https://pubchem.ncbi.nlm.nih.gov/compound/9549295,2.5,Protein Tyrosine Kinase,"PDGFR,VEGFR","KRN 633 is an ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 170 nM/160 nM/125 nM, weakly inhibits PDGFR-α/β and c-Kit, does not block the phosphorylation of FGFR-1, EGFR or c-Met in cell.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40534.nd2.tif_merged.tif
1.3,E16,35,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AT7867,857531-00-1,337.85,https://pubchem.ncbi.nlm.nih.gov/compound/11175137,2.5,PI3K/Akt/mTOR,"Akt,S6 Kinase","AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM in cell-free assays, respectively; little activity outside the AGC kinase family.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40535.nd2.tif_merged.tif
1.3,F16,36,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BMS-777607,1025720-94-8,512.89,https://pubchem.ncbi.nlm.nih.gov/compound/24794418,2.5,Protein Tyrosine Kinase,"TAM Receptor,c-Met","BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases. Phase 1/2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40536.nd2.tif_merged.tif
1.3,G16,37,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PD318088,391210-00-7,561.09,https://pubchem.ncbi.nlm.nih.gov/compound/10231331,2.5,MAPK,MEK,"PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor, binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40537.nd2.tif_merged.tif
1.3,G17,38,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,KU-60019,925701-49-1,547.67,https://pubchem.ncbi.nlm.nih.gov/compound/15953870,2.5,DNA Damage,ATM/ATR,"KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM in cell-free assays, 270- and 1600-fold more selective for ATM than DNA-PK and ATR,and is a highly effective radiosensitizer.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40538.nd2.tif_merged.tif
1.3,F17,39,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BS-181 HCl,1397219-81-6,416.99,https://pubchem.ncbi.nlm.nih.gov/compound/49867928,2.5,Cell Cycle,CDK,"BS-181 HCl is a highly selective CDK7 inhibitor with IC50 of 21 nM. It is more than 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40539.nd2.tif_merged.tif
1.3,E17,40,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Fasudil HCl,105628-07-7,327.83,https://pubchem.ncbi.nlm.nih.gov/compound/163751,2.5,Cell Cycle,"Autophagy,ROCK","Fasudil (HA-1077) HCl is a potent inhibitor of ROCK-II, PKA,  PKG,  PKC, and MLCK with Ki of 0.33 μM, 1.6 μM, 1.6 μM, 3.3 μM and 36 μM in cell-free assays, respectively.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40540.nd2.tif_merged.tif
1.3,D17,41,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Doramapimod,285983-48-4,527.66,https://pubchem.ncbi.nlm.nih.gov/compound/156422,2.5,MAPK,p38 MAPK,"BIRB 796 (Doramapimod) is a  pan-p38 MAPK inhibitor with IC50 of  38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with Kd of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40541.nd2.tif_merged.tif
1.3,C17,42,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Tie2 kinase inhibitor,948557-43-5,439.53,https://pubchem.ncbi.nlm.nih.gov/compound/23625762,2.5,Protein Tyrosine Kinase,Tie-2,"Tie2 kinase inhibitor is an optimized compound of SB-203580, selective to Tie2 with IC50 of 0.25 μM, 200-fold more potent than p38.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40542.nd2.tif_merged.tif
1.3,C16,43,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,H 89 2HCl,130964-39-5,519.28,https://pubchem.ncbi.nlm.nih.gov/compound/5702541,2.5,PI3K/Akt/mTOR,"PKA,S6 Kinase","H 89 2HCl is a potent PKA inhibitor with Ki of 48 nM in a cell-free assay, 10-fold selective for PKA than PKG,500-fold greater selectivity than PKC, MLCK, calmodulin kinase II and casein kinase I/II.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40543.nd2.tif_merged.tif
1.3,C15,44,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,TWS119,601514-19-6,318.33,https://pubchem.ncbi.nlm.nih.gov/compound/9549289,2.5,PI3K/Akt/mTOR,GSK-3,TWS119 is a GSK-3β inhibitor with IC50 of 30 nM in a cell-free assay; capable of inducing neuronal differentiation and may be useful to stem cell biology.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40544.nd2.tif_merged.tif
1.3,C14,45,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Acadesine,2627-69-2,258.23,https://pubchem.ncbi.nlm.nih.gov/compound/17513,2.5,PI3K/Akt/mTOR,AMPK,"Acadesine (AICAR) results in accumulation of ZMP, which mimics the stimulating effect of AMP on AMPK and AMPK kinase. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40545.nd2.tif_merged.tif
1.3,C13,46,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PF-573228,869288-64-2,491.49,https://pubchem.ncbi.nlm.nih.gov/compound/11612883,2.5,Angiogenesis,FAK,"PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in a cell-free assay, ~50- to 250-fold selective for FAK than Pyk2, CDK1/7 and GSK-3β.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40546.nd2.tif_merged.tif
1.3,C12,47,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BMS-265246,582315-72-8,345.34,https://pubchem.ncbi.nlm.nih.gov/compound/135402864,2.5,Cell Cycle,CDK,BMS-265246 is a potent and selective CDK1/2 inhibitor with IC50 of 6 nM/9 nM in a cell-free assay. It is 25-fold more selective for CDK1/2 than CDK4.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40547.nd2.tif_merged.tif
1.3,C11,48,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Lapatinib,231277-92-2,581.06,https://pubchem.ncbi.nlm.nih.gov/compound/208908,2.5,Protein Tyrosine Kinase,"EGFR,HER2","Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40548.nd2.tif_merged.tif
1.3,C10,49,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40549.nd2.tif_merged.tif
1.3,C9,50,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_1-3_40550.nd2.tif_merged.tif
2.1,C8,1,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZD8330,869357-68-6,461.23,https://pubchem.ncbi.nlm.nih.gov/compound/16666708,2.5,MAPK,MEK,"AZD8330 is a novel, selective, non-ATP competitive MEK 1/2 inhibitor with IC50 of 7 nM. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40501.nd2.tif_merged.tif
2.1,D8,2,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,KW-2449,1000669-72-6,332.4,https://pubchem.ncbi.nlm.nih.gov/compound/11427553,2.5,Angiogenesis,"Aurora Kinase,Bcr-Abl,FLT3","KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 with IC50 of 6.6 nM, modestly potent to FGFR1, Bcr-Abl and Aurora A; little effect on PDGFRβ, IGF-1R, EGFR. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40502.nd2.tif_merged.tif
2.1,E8,3,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,RAF265,927880-90-8,518.41,https://pubchem.ncbi.nlm.nih.gov/compound/11656518,2.5,MAPK,"Raf,VEGFR","RAF265 (CHIR-265) is a potent selective inhibitor of C-Raf/B-Raf/B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30 nM in cell-free assays. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40503.nd2.tif_merged.tif
2.1,F8,4,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZD1480,"935666-88-9, 1260222-79-4 (TFA)",348.77,https://pubchem.ncbi.nlm.nih.gov/compound/16659841,2.5,JAK/STAT,JAK,"AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM in a cell-free assay, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40504.nd2.tif_merged.tif
2.1,G8,5,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PF-4708671,1255517-76-0,390.41,https://pubchem.ncbi.nlm.nih.gov/compound/51371303,2.5,PI3K/Akt/mTOR,S6 Kinase,"PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40505.nd2.tif_merged.tif
2.1,G9,6,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Gandotinib,1229236-86-5,469.94,https://pubchem.ncbi.nlm.nih.gov/compound/46213929,2.5,JAK/STAT,JAK,"Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40506.nd2.tif_merged.tif
2.1,F9,7,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AST-1306,1050500-29-2,621.08,https://pubchem.ncbi.nlm.nih.gov/compound/25027665,2.5,Protein Tyrosine Kinase,EGFR,"AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40507.nd2.tif_merged.tif
2.1,E9,8,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Sapitinib,848942-61-0,473.93,https://pubchem.ncbi.nlm.nih.gov/compound/11488320,2.5,Protein Tyrosine Kinase,"EGFR,HER2","Sapitinib (AZD8931) is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM in cell-free assays, more potent than Gefitinib or Lapatinib against NSCLC cell, 100-fold more selective for the ErbB family than MNK1 and Flt. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40508.nd2.tif_merged.tif
2.1,D9,9,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GSK461364,929095-18-1,543.6,https://pubchem.ncbi.nlm.nih.gov/compound/15983966,2.5,Cell Cycle,PLK,GSK461364 inhibits purified Plk1 with Ki of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40509.nd2.tif_merged.tif
2.1,D10,10,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,R406,841290-81-1,628.63,https://pubchem.ncbi.nlm.nih.gov/compound/11984591,2.5,Angiogenesis,"FLT3,Syk","R406 is a potent Syk inhibitor with IC50 of 41 nM in cell-free assays, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40510.nd2.tif_merged.tif
2.1,E10,11,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SGI-1776,1025065-69-3,405.42,https://pubchem.ncbi.nlm.nih.gov/compound/24795070,2.5,JAK/STAT,Pim,"SGI-1776 free base is a novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM in a cell-free assay, 50- and 10-fold selective versus Pim2 and Pim3, also potent to Flt3 and haspin. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40511.nd2.tif_merged.tif
2.1,F10,12,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BMS-794833,1174046-72-0,468.84,https://pubchem.ncbi.nlm.nih.gov/compound/44155856,2.5,Protein Tyrosine Kinase,"c-Met,VEGFR","BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7 nM/15 nM, also inhibits Ron, Axl and Flt3 with IC50 of <3 nM; a prodrug of BMS-817378. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40512.nd2.tif_merged.tif
2.1,G10,13,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,NVP-BHG712,940310-85-0,503.48,https://pubchem.ncbi.nlm.nih.gov/compound/16747388,2.5,Protein Tyrosine Kinase,"Bcr-Abl,Ephrin receptor,Raf,Src","NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40513.nd2.tif_merged.tif
2.1,G11,14,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,OSI-420,183320-51-6,415.87,https://pubchem.ncbi.nlm.nih.gov/compound/18924996,2.5,Protein Tyrosine Kinase,EGFR,OSI-420 is the active metabolite of Erlotinib (EGFR inhibitor with IC50 of 2 nM).,,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40514.nd2.tif_merged.tif
2.1,F11,15,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PIK-293,900185-01-5,397.43,https://pubchem.ncbi.nlm.nih.gov/compound/53245636,2.5,PI3K/Akt/mTOR,PI3K,"PIK-293 is a PI3K inhibitor, mostly for PI3Kδ with IC50 of 0.24 μM, 500-, 100- and 50-fold less potent to PI3Kα/β/γ, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40515.nd2.tif_merged.tif
2.1,E11,16,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZ 960,905586-69-8,354.36,https://pubchem.ncbi.nlm.nih.gov/compound/25099184,2.5,JAK/STAT,JAK,"AZ 960 is a novel ATP competitive JAK2 inhibitor with IC50 and Ki of <3 nM and 0.45 nM, 3-fold selectivity of AZ960 for JAK2 over JAK3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40516.nd2.tif_merged.tif
2.1,D11,17,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Mubritinib,366017-09-6,468.47,https://pubchem.ncbi.nlm.nih.gov/compound/6444692,2.5,Protein Tyrosine Kinase,HER2,"Mubritinib (TAK-165) is a potent inhibitor of HER2/ErbB2 with IC50 of 6 nM in BT-474 cell; no activity to EGFR, FGFR, PDGFR, JAK1, Src and Blk in BT-474 cell line. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40517.nd2.tif_merged.tif
2.1,D12,18,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Torkinib,1092351-67-1,308.34,https://pubchem.ncbi.nlm.nih.gov/compound/135565635,2.5,PI3K/Akt/mTOR,"Autophagy,mTOR","Torkinib (PP242) is a selective mTOR inhibitor with IC50 of 8 nM in cell-free assays; targets both mTOR complexes with >10- and 100-fold selectivity for mTOR than PI3Kδ or PI3Kα/β/γ, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40518.nd2.tif_merged.tif
2.1,E12,19,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Momelotinib,1056634-68-4,414.46,https://pubchem.ncbi.nlm.nih.gov/compound/25062766,2.5,JAK/STAT,JAK,"Momelotinib (CYT387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, ~10-fold selectivity versus JAK3. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40519.nd2.tif_merged.tif
2.1,F12,20,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SB590885,405554-55-4,453.54,https://pubchem.ncbi.nlm.nih.gov/compound/135421339,2.5,MAPK,Raf,"SB590885 is a potent B-Raf inhibitor with Ki of 0.16 nM in a cell-free assay, 11-fold greater selectivity for B-Raf over c-Raf, no inhibition to other human kinases.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40520.nd2.tif_merged.tif
2.1,G12,21,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Apatinib,811803-05-1,493.58,https://pubchem.ncbi.nlm.nih.gov/compound/11315474,2.5,Protein Tyrosine Kinase,VEGFR,"Apatinib is an orally bioavailable, selective VEGFR2 inhibitor with IC50 of 1 nM.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40521.nd2.tif_merged.tif
2.1,G13,22,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Idelalisib,870281-82-6,415.42,https://pubchem.ncbi.nlm.nih.gov/compound/11625818,2.5,PI3K/Akt/mTOR,PI3K,"Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40522.nd2.tif_merged.tif
2.1,F13,23,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PIK-294,900185-02-6,489.53,https://pubchem.ncbi.nlm.nih.gov/compound/24905149,2.5,PI3K/Akt/mTOR,PI3K,"PIK-294 is a highly selective p110δ inhibitor with IC50 of 10 nM, 1000-, 49- and 16-fold less potent to PI3Kα/β/γ, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40523.nd2.tif_merged.tif
2.1,E13,24,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Telatinib,332012-40-5,409.83,https://pubchem.ncbi.nlm.nih.gov/compound/9808844,2.5,Protein Tyrosine Kinase,"c-Kit,PDGFR,VEGFR","Telatinib is a potent inhibitor of VEGFR2/3, c-Kit and PDGFRα with IC50 of 6 nM/4 nM, 1 nM and 15 nM, respectively. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40524.nd2.tif_merged.tif
2.1,D13,25,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Volasertib,755038-65-4,618.81,https://pubchem.ncbi.nlm.nih.gov/compound/10461508,2.5,Cell Cycle,PLK,Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40525.nd2.tif_merged.tif
2.1,D14,26,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Palomid 529,914913-88-5,406.43,https://pubchem.ncbi.nlm.nih.gov/compound/11998575,2.5,PI3K/Akt/mTOR,mTOR,"Palomid 529 (P529) inhibits both the mTORC1 and mTORC2 complexes, reduces phosphorylation of pAktS473, pGSK3βS9, and pS6 but no effect observed on pMAPK or pAktT308. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40526.nd2.tif_merged.tif
2.1,E14,27,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Degrasyn,856243-80-6,384.27,https://pubchem.ncbi.nlm.nih.gov/compound/11222830,2.5,Angiogenesis,"Bcr-Abl,DUB","Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40527.nd2.tif_merged.tif
2.1,F14,28,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Buparlisib,944396-07-0,410.39,https://pubchem.ncbi.nlm.nih.gov/compound/16654980,2.5,PI3K/Akt/mTOR,PI3K,"Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40528.nd2.tif_merged.tif
2.1,G14,29,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Asiatic Acid,464-92-6,488.7,https://pubchem.ncbi.nlm.nih.gov/compound/119034,2.5,MAPK,p38 MAPK,"Asiatic acid is the aglycone of asiaticoside isolated from the plant Centella asiatica, commonly used in wound healing. ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40529.nd2.tif_merged.tif
2.1,G15,30,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Honokiol,35354-74-6,266.334,https://pubchem.ncbi.nlm.nih.gov/compound/72303,2.5,PI3K/Akt/mTOR,"Akt,MEK",Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40530.nd2.tif_merged.tif
2.1,F15,31,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Indirubin,479-41-4,262.26,https://pubchem.ncbi.nlm.nih.gov/compound/10177,2.5,PI3K/Akt/mTOR,GSK-3,Indirubin is a potent cyclin-dependent kinases and GSK-3β inhibitor with IC50 of about 5 μM and 0.6 μM.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40531.nd2.tif_merged.tif
2.1,E15,32,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Quercetin,117-39-5,302.24,https://pubchem.ncbi.nlm.nih.gov/compound/5280343,2.5,Epigenetics,"Src,Sirtuin,PKC,PI3K","Quercetin, a natural flavonoid present in vegetables, fruit and wine, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4-5.4 μM. Phase 4.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40532.nd2.tif_merged.tif
2.1,D15,33,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Chrysophanic Acid,481-74-3,254.24,https://pubchem.ncbi.nlm.nih.gov/compound/10208,2.5,Protein Tyrosine Kinase,"EGFR,mTOR","Chrysophanic acid (Chrysophanol), a natural anthraquinone isolated from Dianella longifolia, is a EGFR/mTOR pathway inhibitor.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40533.nd2.tif_merged.tif
2.1,D16,34,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Phenformin HCl,834-28-6,241.72,https://pubchem.ncbi.nlm.nih.gov/compound/13266,2.5,PI3K/Akt/mTOR,AMPK,Phenformin HCl is a hydrochloride salt of phenformin that is an anti-diabetic drug from the biguanide class.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40534.nd2.tif_merged.tif
2.1,E16,35,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Daphnetin,486-35-1,178.14,https://pubchem.ncbi.nlm.nih.gov/compound/5280569,2.5,DNA Damage,"PKA,EGFR,PKC","Daphnetin, a natural coumarin derivative, is a protein kinase inhibitor, inhibits EGFR, PKA and PKC with IC50 of 7.67 μM, 9.33 μM and 25.01 μM, respectively, also known to exhibit anti-inflammatory and anti-oxidant activities.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40535.nd2.tif_merged.tif
2.1,F16,36,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,TAK-733,1035555-63-5,504.23,https://pubchem.ncbi.nlm.nih.gov/compound/24963252,2.5,MAPK,MEK,"TAK-733 is a potent and selective MEK allosteric site inhibitor for MEK1 with IC50 of 3.2 nM, inactive to Abl1, AKT3, c-RAF, CamK1, CDK2, c-Met, etc. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40536.nd2.tif_merged.tif
2.1,G16,37,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZD5438,602306-29-6,371.46,https://pubchem.ncbi.nlm.nih.gov/compound/16747683,2.5,Cell Cycle,CDK,AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM in cell-free assays. It is less potent to CDK5/6 and also inhibits GSK3β. Phase 1.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40537.nd2.tif_merged.tif
2.1,G17,38,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PP121,1092788-83-4,319.36,https://pubchem.ncbi.nlm.nih.gov/compound/24905142,2.5,Protein Tyrosine Kinase,"DNA-PK,mTOR,PDGFR","PP121 is a multi-targeted inhibitor of PDGFR, Hck, mTOR, VEGFR2, Src and Abl with IC50 of 2 nM, 8 nM, 10 nM, 12 nM, 14 nM and 18 nM, also inhibits DNA-PK with IC50 of 60 nM.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40538.nd2.tif_merged.tif
2.1,F17,39,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,OSI-027,936890-98-1,406.44,https://pubchem.ncbi.nlm.nih.gov/compound/135398516,2.5,PI3K/Akt/mTOR,mTOR,"OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM in cell-free assays, and more than 100-fold selectivity observed for mTOR than PI3Kα, PI3Kβ, PI3Kγ or DNA-PK. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40539.nd2.tif_merged.tif
2.1,E17,40,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Fostamatinib,901119-35-5,580.46,https://pubchem.ncbi.nlm.nih.gov/compound/11671467,2.5,Angiogenesis,Syk,"Fostamatinib (R788), a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40540.nd2.tif_merged.tif
2.1,D17,41,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,LY2603618,911222-45-2,436.3,https://pubchem.ncbi.nlm.nih.gov/compound/11955855,2.5,Cell Cycle,Chk,LY2603618 is a selective Chk1 inhibitor with potential anti-tumor activity in a cell-free assay. Phase 2.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40541.nd2.tif_merged.tif
2.1,C17,42,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Rebastinib,1020172-07-9,553.59,https://pubchem.ncbi.nlm.nih.gov/compound/25066467,2.5,Angiogenesis,Bcr-Abl,"Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40542.nd2.tif_merged.tif
2.1,C16,43,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CCT128930,885499-61-6,341.84,https://pubchem.ncbi.nlm.nih.gov/compound/17751819,2.5,PI3K/Akt/mTOR,Akt,"CCT128930 is a potent, ATP-competitive and selective inhibitor of Akt2 with IC50 of 6 nM in a cell-free assay, 28-fold greater selectivity for Akt2 than the closely related PKA kinase.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40543.nd2.tif_merged.tif
2.1,C15,44,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,A66,1166227-08-2,393.53,https://pubchem.ncbi.nlm.nih.gov/compound/42636535,2.5,PI3K/Akt/mTOR,PI3K,"A66 is a potent and specific p110α inhibitor with IC50 of 32 nM in a cell-free assay, >100 fold selectivity for p110α over other class-I PI3K isoforms.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40544.nd2.tif_merged.tif
2.1,C14,45,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Omipalisib,1086062-66-9,505.5,https://pubchem.ncbi.nlm.nih.gov/compound/25167777,2.5,PI3K/Akt/mTOR,"mTOR,PI3K","Omipalisib (GSK2126458, GSK458) is a highly selective and potent inhibitor of p110α/β/δ/γ, mTORC1/2 with Ki of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM in cell-free assays, respectively. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40545.nd2.tif_merged.tif
2.1,C13,46,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,WYE-125132,1144068-46-1,519.6,https://pubchem.ncbi.nlm.nih.gov/compound/25260757,2.5,PI3K/Akt/mTOR,mTOR,"WYE-125132 (WYE-132) is a highly potent, ATP-competitive mTOR inhibitor with IC50 of 0.19 nM; highly selective for mTOR versus PI3Ks or PI3K-related kinases hSMG1 and ATR.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40546.nd2.tif_merged.tif
2.1,C12,47,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,A-674563,552325-73-2,358.44,https://pubchem.ncbi.nlm.nih.gov/compound/11314340,2.5,PI3K/Akt/mTOR,"Akt,CDK,PKA","A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40547.nd2.tif_merged.tif
2.1,C11,48,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AS-252424,900515-16-4,305.28,https://pubchem.ncbi.nlm.nih.gov/compound/11630874,2.5,PI3K/Akt/mTOR,PI3K,"AS-252424 is a novel, potent PI3Kγ inhibitor with IC50 of 30 nM in a cell-free assay with 30-fold selectivity for PI3Kγ than PI3Kα, and low inhibitory activity towards PI3Kδ/β.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40548.nd2.tif_merged.tif
2.1,C10,49,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40549.nd2.tif_merged.tif
2.1,C9,50,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-1_40550.nd2.tif_merged.tif
2.2,C8,1,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PF-00562271,939791-38-5,665.66,https://pubchem.ncbi.nlm.nih.gov/compound/16118986,2.5,Angiogenesis,FAK,"PF-00562271 is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40501.nd2.tif_merged.tif
2.2,D8,2,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Trametinib,871700-17-3,615.39,https://pubchem.ncbi.nlm.nih.gov/compound/11707110,2.5,MAPK,MEK,"Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40502.nd2.tif_merged.tif
2.2,E8,3,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Flavopiridol HCl,131740-09-5,438.3,https://pubchem.ncbi.nlm.nih.gov/compound/9910986,2.5,Cell Cycle,CDK,"Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40503.nd2.tif_merged.tif
2.2,F8,4,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Ibrutinib,936563-96-1,440.5,https://pubchem.ncbi.nlm.nih.gov/compound/24821094,2.5,Angiogenesis,BTK,"Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40504.nd2.tif_merged.tif
2.2,G8,5,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AS-604850,648449-76-7,285.22,https://pubchem.ncbi.nlm.nih.gov/compound/5287855,2.5,PI3K/Akt/mTOR,PI3K,"AS-604850 is a selective, ATP-competitive PI3Kγ inhibitor with IC50 of 250 nM, over 80-fold selectivity for PI3Kγ than PI3Kδ/β, and 18-fold more selective for PI3Kγ than PI3Kα.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40505.nd2.tif_merged.tif
2.2,G9,6,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CAY10505,1218777-13-9 ,289.28,https://pubchem.ncbi.nlm.nih.gov/compound/1204893,2.5,PI3K/Akt/mTOR,PI3K,"CAY10505 is dehydroxyl of AS-252424, which is a PI3Kγ inhibitor with IC50 of 33 nM.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40506.nd2.tif_merged.tif
2.2,F9,7,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CHIR-124,405168-58-3,419.91,https://pubchem.ncbi.nlm.nih.gov/compound/135399748,2.5,Cell Cycle,Chk,"CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM in a cell-free assay. It shows 2,000-fold selectivity against Chk2, 500- to 5,000-fold less activity against CDK2/4 and Cdc2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40507.nd2.tif_merged.tif
2.2,E9,8,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,NVP-BSK805 2HCl,1092499-93-8 (free base),563.47,https://pubchem.ncbi.nlm.nih.gov/compound/57339395,2.5,JAK/STAT,JAK,"NVP-BSK805 2HCl is a potent and selective ATP-competitive JAK2 inhibitor with IC50 of 0.5 nM,>20-fold selectivity towards JAK1, JAK3 and TYK2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40508.nd2.tif_merged.tif
2.2,D9,9,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,R547,741713-40-6,441.45,https://pubchem.ncbi.nlm.nih.gov/compound/6918852,2.5,Cell Cycle,CDK,"R547 is a potent ATP-competitive inhibitor of CDK1/2/4 with Ki of 2 nM/3 nM/1 nM. It is less potent to CDK7 and GSK3α/β, while inactive to other kinases. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40509.nd2.tif_merged.tif
2.2,D10,10,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,WAY-600,1062159-35-6,494.59,https://pubchem.ncbi.nlm.nih.gov/compound/25229526,2.5,PI3K/Akt/mTOR,mTOR,"WAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM; blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) but not P-AKT(T308); selective for mTOR than PI3Kα (>100-fold) and PI3Kγ (>500-fold). ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40510.nd2.tif_merged.tif
2.2,E10,11,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,TG101209,936091-14-4,509.67,https://pubchem.ncbi.nlm.nih.gov/compound/16722832,2.5,JAK/STAT,"c-RET,FLT3,JAK","TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM, less potent to Flt3 and RET with IC50 of 25 nM and 17 nM in cell-free assays, ~30-fold selective for JAK2 than JAK3, sensitive to JAK2V617F and MPLW515L/K mutations.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40511.nd2.tif_merged.tif
2.2,F10,12,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Apitolisib,1032754-93-0,498.6,https://pubchem.ncbi.nlm.nih.gov/compound/25254071,2.5,PI3K/Akt/mTOR,"mTOR,PI3K","Apitolisib (GDC-0980, RG7422) is a potent, class I PI3K inhibitor for PI3Kα/β/δ/γ with IC50 of 5 nM/27 nM/7 nM/14 nM in cell-free assays, respectively. Also a mTOR inhibitor with Ki of 17 nM in a cell-free assay, and highly selective versus other PIKK family kinases. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40512.nd2.tif_merged.tif
2.2,G10,13,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,A-769662,844499-71-4,360.39,https://pubchem.ncbi.nlm.nih.gov/compound/54708532,2.5,PI3K/Akt/mTOR,AMPK,"A-769662 is a potent, reversible AMPK activator with EC50 of 0.8 μM in cell-free assays, little effect on GPPase/FBPase activity.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40513.nd2.tif_merged.tif
2.2,G11,14,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CH5132799,1007207-67-1,377.42,https://pubchem.ncbi.nlm.nih.gov/compound/49784945,2.5,PI3K/Akt/mTOR,"mTOR,PI3K","CH5132799 inhibits class I PI3Ks, particularly PI3Kα with IC50 of 14 nM; less potent to PI3Kβδγ, while sensitive in PIK3CA mutations cell lines. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40514.nd2.tif_merged.tif
2.2,F11,15,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,KX2-391,897016-82-9,431.53,https://pubchem.ncbi.nlm.nih.gov/compound/23635314,2.5,Angiogenesis,Src,"KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40515.nd2.tif_merged.tif
2.2,E11,16,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GSK1838705A,1116235-97-2,532.57,https://pubchem.ncbi.nlm.nih.gov/compound/25182616,2.5,Protein Tyrosine Kinase,"ALK,IGF-1R","GSK1838705A is a potent IGF-1R inhibitor with IC50 of 2.0 nM, modestly potent to IR and ALK with IC50 of 1.6 nM and 0.5 nM, respectively, and little activity to other protein kinases.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40516.nd2.tif_merged.tif
2.2,D11,17,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,TAK-901,934541-31-8,504.64,https://pubchem.ncbi.nlm.nih.gov/compound/16124208,2.5,Cell Cycle,Aurora Kinase,"TAK-901 is a novel inhibitor of Aurora A/B with IC50 of 21 nM/15 nM. It is not a potent inhibitor of cellular JAK2, c-Src or Abl. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40517.nd2.tif_merged.tif
2.2,D12,18,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AMG-900,945595-80-2,503.58,https://pubchem.ncbi.nlm.nih.gov/compound/24856041,2.5,Cell Cycle,Aurora Kinase,"AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A/B/C with IC50 of 5 nM/4 nM /1 nM. It is >10-fold selective for Aurora kinases than p38α, Tyk2, JNK2, Met and Tie2. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40518.nd2.tif_merged.tif
2.2,E12,19,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,ZM 336372,208260-29-1,389.45,https://pubchem.ncbi.nlm.nih.gov/compound/5730,2.5,MAPK,Raf,"ZM 336372 is a potent and selective c-Raf inhibitor with IC50 of 70 nM, 10-fold selectivity over B-RAF, no inhibition to PKA/B/C, AMPK, p70S6, etc.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40519.nd2.tif_merged.tif
2.2,F12,20,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PH-797804,586379-66-0,477.3,https://pubchem.ncbi.nlm.nih.gov/compound/22049997,2.5,MAPK,p38 MAPK,PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40520.nd2.tif_merged.tif
2.2,G12,21,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Dacomitinib,1110813-31-4,469.94,https://pubchem.ncbi.nlm.nih.gov/compound/11511120,2.5,Protein Tyrosine Kinase,EGFR,"Dacomitinib (PF299804, PF299) is a potent, irreversible pan-ErbB inhibitor, mostly to EGFR with IC50 of 6 nM in a cell-free assay, effective against NSCLCs with EGFR or ERBB2 mutations (resistant to gefitinib) as well as those harboring the EGFR T790M mutation. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40521.nd2.tif_merged.tif
2.2,G13,22,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AG-1478,153436-53-4,315.75,https://pubchem.ncbi.nlm.nih.gov/compound/2051,2.5,Protein Tyrosine Kinase,EGFR,"AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40522.nd2.tif_merged.tif
2.2,F13,23,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SB415286,264218-23-7,359.72,https://pubchem.ncbi.nlm.nih.gov/compound/4210951,2.5,PI3K/Akt/mTOR,GSK-3,SB415286 is a potent GSK3α inhibitor with IC50/Ki of 78 nM/31 nM with equally effective inhibition of GSK-3β.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40523.nd2.tif_merged.tif
2.2,E13,24,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Crenolanib,670220-88-9,443.54,https://pubchem.ncbi.nlm.nih.gov/compound/10366136,2.5,Protein Tyrosine Kinase,PDGFR,"Crenolanib (CP-868596) is a potent and selective inhibitor of PDGFRα/β with Kd of 2.1 nM/3.2 nM in CHO cells, also potently inhibits FLT3, sensitive to D842V mutation not V561D mutation, >100-fold more selective for PDGFR than c-Kit, VEGFR-2, TIE-2, FGFR-2, EGFR, erbB2, and Src.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40524.nd2.tif_merged.tif
2.2,D13,25,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Fedratinib,936091-26-8,524.68,https://pubchem.ncbi.nlm.nih.gov/compound/16722836,2.5,JAK/STAT,JAK,"Fedratinib (SAR302503, TG101348) is a selective inhibitor of JAK2 with IC50 of 3 nM in cell-free assays, 35- and 334-fold more selective for JAK2 versus JAK1 and JAK3. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40525.nd2.tif_merged.tif
2.2,D14,26,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PHA-767491,942425-68-5,249.7,https://pubchem.ncbi.nlm.nih.gov/compound/11715766,2.5,Cell Cycle,CDK,"PHA-767491 is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM in cell-free assays, respectively.It displays ~20-fold selectivity against CDK1/2 and GSK3-β, 50-fold selectivity against MK2 and CDK5, 100-fold selectivity against PLK1 and CHK2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40526.nd2.tif_merged.tif
2.2,E14,27,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PF-04691502,1013101-36-4,425.48,https://pubchem.ncbi.nlm.nih.gov/compound/25033539,2.5,PI3K/Akt/mTOR,"Akt,mTOR,PI3K","PF-04691502 is an ATP-competitive PI3K(α/β/δ/γ)/mTOR dual inhibitor with Ki of 1.8 nM/2.1 nM/1.6 nM/1.9 nM and 16 nM in cell-free assays, little activity against either Vps34, AKT, PDK1, p70S6K, MEK, ERK, p38, or JNK. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40527.nd2.tif_merged.tif
2.2,F14,28,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CHIR-98014,252935-94-7,486.31,https://pubchem.ncbi.nlm.nih.gov/compound/53396311,2.5,PI3K/Akt/mTOR,GSK-3,"CHIR-98014 is a potent GSK-3α/β inhibitor with IC50 of 0.65 nM/0.58 nM in cell-free assays, with the ability to distinguish GSK-3 from its closest homologs Cdc2 and ERK2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40528.nd2.tif_merged.tif
2.2,G14,29,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZ 628,878739-06-1,451.52,https://pubchem.ncbi.nlm.nih.gov/compound/11676786,2.5,MAPK,Raf,"AZ628 is a new pan-Raf inhibitor for BRAF, BRAFV600E, and c-Raf-1 with IC50 of 105 nM, 34 nM and 29 nM in cell-free assays, also inhibits VEGFR2, DDR2, Lyn, Flt1, FMS, etc.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40529.nd2.tif_merged.tif
2.2,G15,30,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AMG-458,913376-83-7,539.58,https://pubchem.ncbi.nlm.nih.gov/compound/24764449,2.5,Protein Tyrosine Kinase,c-Met,"AMG 458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40530.nd2.tif_merged.tif
2.2,F15,31,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BGT226,1245537-68-1,650.6,https://pubchem.ncbi.nlm.nih.gov/compound/57336745,2.5,PI3K/Akt/mTOR,"mTOR,PI3K",BGT226 (NVP-BGT226) is a novel class I PI3K/mTOR inhibitor for PI3Kα/β/γ with IC50 of 4 nM/63 nM/38 nM. Phase 1/2.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40531.nd2.tif_merged.tif
2.2,E15,32,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Milciclib,802539-81-7,460.57,https://pubchem.ncbi.nlm.nih.gov/compound/16718576,2.5,Cell Cycle,CDK,"Milciclib (PHA-848125) is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40532.nd2.tif_merged.tif
2.2,D15,33,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Tivantinib,905854-02-6,369.42,https://pubchem.ncbi.nlm.nih.gov/compound/11494412,2.5,Protein Tyrosine Kinase,c-Met,"Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM in a cell-free assay, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40533.nd2.tif_merged.tif
2.2,D16,34,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Varlitinib,845272-21-1,466.94,https://pubchem.ncbi.nlm.nih.gov/compound/42642648,2.5,Protein Tyrosine Kinase,EGFR,"Varlitinib is a selective and potent ErbB1(EGFR) and ErbB2(HER2) inhibitor with IC50 of 7 nM and 2 nM, respectively. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40534.nd2.tif_merged.tif
2.2,E16,35,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CUDC-907,1339928-25-4,508.55,https://pubchem.ncbi.nlm.nih.gov/compound/54575456,2.5,Cytoskeletal Signaling,"HDAC,PI3K","CUDC-907 is a dual PI3K and HDAC inhibitor for PI3Kα and HDAC1/2/3/10 with IC50 of 19 nM and 1.7 nM/5 nM/1.8 nM/2.8 nM, respectively. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40535.nd2.tif_merged.tif
2.2,F16,36,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,NVP-BVU972,1185763-69-2,340.38,https://pubchem.ncbi.nlm.nih.gov/compound/44206063,2.5,Protein Tyrosine Kinase,c-Met,NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40536.nd2.tif_merged.tif
2.2,G16,37,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,3-Methyladenine,5142-23-4,149.15,https://pubchem.ncbi.nlm.nih.gov/compound/135398661,2.5,PI3K/Akt/mTOR,"Autophagy,PI3K","3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells;  blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40537.nd2.tif_merged.tif
2.2,G17,38,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Dinaciclib,779353-01-4,396.49,https://pubchem.ncbi.nlm.nih.gov/compound/46926350,2.5,Cell Cycle,CDK,"Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40538.nd2.tif_merged.tif
2.2,F17,39,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Dovitinib Dilactic Acid,852433-84-2,572.59,https://pubchem.ncbi.nlm.nih.gov/compound/135985126,2.5,Angiogenesis,"c-Kit,FGFR,FLT3,PDGFR,VEGFR","Dovitinib Dilactic acid (TKI258 Dilactic acid) is the Dilactic acid of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGFR1 and HER2. Phase 4.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40539.nd2.tif_merged.tif
2.2,E17,40,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,MK-5108,1010085-13-8,461.94,https://pubchem.ncbi.nlm.nih.gov/compound/24748204,2.5,Cell Cycle,Aurora Kinase,"MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40540.nd2.tif_merged.tif
2.2,D17,41,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,MK-2461,917879-39-1,495.55,https://pubchem.ncbi.nlm.nih.gov/compound/44137946,2.5,Protein Tyrosine Kinase,"c-Met,FGFR,PDGFR","MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFRβ, KDR, Flt3, Flt4, TrkA, and TrkB. Phase 1/2. .",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40541.nd2.tif_merged.tif
2.2,C17,42,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Vistusertib,1009298-59-2,462.54,https://pubchem.ncbi.nlm.nih.gov/compound/25262792,2.5,PI3K/Akt/mTOR,mTOR,Vistusertib (AZD2014) is a novel mTOR inhibitor with IC50 of 2.8 nM in a cell-free assay; highly selective against multiple PI3K isoforms (α/β/γ/δ). Phase 2.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40542.nd2.tif_merged.tif
2.2,C16,43,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,TAK-285,871026-44-7,547.96,https://pubchem.ncbi.nlm.nih.gov/compound/11620908,2.5,Protein Tyrosine Kinase,"EGFR,HER2","TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40543.nd2.tif_merged.tif
2.2,C15,44,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Tofacitinib,477600-75-2,312.37,https://pubchem.ncbi.nlm.nih.gov/compound/9926791,2.5,JAK/STAT,JAK,"Tofacitinib (CP-690550,Tasocitinib) is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40544.nd2.tif_merged.tif
2.2,C14,45,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Sotrastaurin,425637-18-9,438.48,https://pubchem.ncbi.nlm.nih.gov/compound/10296883,2.5,TGF-beta/Smad,PKC,"Sotrastaurin is a potent and selective pan-PKC inhibitor, mostly for PKCθ with Ki of 0.22 nM in a cell-free assay; inactive to PKCζ. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40545.nd2.tif_merged.tif
2.2,C13,46,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,WP1066,857064-38-1,356.22,https://pubchem.ncbi.nlm.nih.gov/compound/11210478,2.5,JAK/STAT,JAK,"WP1066 is a novel inhibitor of JAK2 and STAT3 with IC50 of 2.30 μM and 2.43 μM in HEL cells; shows activity to JAK2, STAT3, STAT5, and ERK1/2 not JAK1 and JAK3. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40546.nd2.tif_merged.tif
2.2,C12,47,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZD4547,1035270-39-3,463.57,https://pubchem.ncbi.nlm.nih.gov/compound/51039095,2.5,Angiogenesis,FGFR,"AZD4547 is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40547.nd2.tif_merged.tif
2.2,C11,48,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CEP-33779,1257704-57-6,462.57,https://pubchem.ncbi.nlm.nih.gov/compound/57336812,2.5,JAK/STAT,JAK,"CEP-33779 is a selective JAK2 inhibitor with IC50 of 1.8 nM, >40- and >800-fold versus JAK1 and TYK2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40548.nd2.tif_merged.tif
2.2,C10,49,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40549.nd2.tif_merged.tif
2.2,C9,50,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-2_40550.nd2.tif_merged.tif
2.3,C8,1,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Dabrafenib,1195765-45-7,519.56,https://pubchem.ncbi.nlm.nih.gov/compound/44462760,2.5,MAPK,Raf,"Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM in cell-free assays, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40501.nd2.tif_merged.tif
2.3,D8,2,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Ipatasertib,1001264-89-6,458,https://pubchem.ncbi.nlm.nih.gov/compound/24788740,2.5,PI3K/Akt/mTOR,Akt,"Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40502.nd2.tif_merged.tif
2.3,E8,3,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,INK 128,1224844-38-5,309.33,https://pubchem.ncbi.nlm.nih.gov/compound/45375953,2.5,PI3K/Akt/mTOR,mTOR,"INK 128 (MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40503.nd2.tif_merged.tif
2.3,F8,4,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Alpelisib,1217486-61-7,441.47,https://pubchem.ncbi.nlm.nih.gov/compound/56649450,2.5,PI3K/Akt/mTOR,PI3K,"Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40504.nd2.tif_merged.tif
2.3,G8,5,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Tyrphostin AG 879,148741-30-4,316.46,https://pubchem.ncbi.nlm.nih.gov/compound/135419190,2.5,Protein Tyrosine Kinase,HER2,"Tyrphostin AG 879 potently inhibits HER2/ErbB2 with IC50 of 1 μM, 100- and 500-fold higher selective to ErbB2 than PDGFR and EGFR.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40505.nd2.tif_merged.tif
2.3,G9,6,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Torin 2,1223001-51-1,432.4,https://pubchem.ncbi.nlm.nih.gov/compound/51358113,2.5,PI3K/Akt/mTOR,"ATM/ATR,mTOR","Torin 2 is a potent and selective mTOR inhibitor with IC50 of 0.25 nM in p53−/− MEFs cell line; 800-fold greater selectivity for mTOR than PI3K and improved pharmacokinetic properties. Inhibition of ATM/ATR/DNA-PK with EC50 of 28 nM/35 nM/118 nM,in PC3 cell lines respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40506.nd2.tif_merged.tif
2.3,F9,7,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,TAE226,761437-28-9,468.94,https://pubchem.ncbi.nlm.nih.gov/compound/9934347,2.5,Angiogenesis,FAK,"TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40507.nd2.tif_merged.tif
2.3,E9,8,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Tideglusib,865854-05-3 ,334.39,https://pubchem.ncbi.nlm.nih.gov/compound/11313622,2.5,PI3K/Akt/mTOR,GSK-3,"Tideglusib is an irreversible, non ATP-competitive GSK-3β inhibitor with IC50 of 60 nM in a cell-free assay; fails to inhibit kinases with a Cys homologous to Cys-199 located in the active site. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40508.nd2.tif_merged.tif
2.3,D9,9,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,TPCA-1,507475-17-4,279.29,https://pubchem.ncbi.nlm.nih.gov/compound/9903786,2.5,NF-κB,IκB/IKK,"TPCA-1 is an inhibitor of IKK-2 with IC50 of 17.9 nM in a cell-free assay, inhibits NF-κB pathway, exhibits 22-fold selectivity over IKK-1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40509.nd2.tif_merged.tif
2.3,D10,10,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SAR131675,1433953-83-3,358.39,https://pubchem.ncbi.nlm.nih.gov/compound/71295845,2.5,Protein Tyrosine Kinase,VEGFR,"SAR131675 is a VEGFR3 inhibitor with IC50/Ki of 23 nM/12 nM in cell-free assays, about 50- and 10-fold more selective for VEGFR3 than VEGFR1/2, little activity against Akt1, CDKs, PLK1, EGFR, IGF-1R, c-Met, Flt2 etc.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40510.nd2.tif_merged.tif
2.3,E10,11,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BI-D1870,501437-28-1,391.42,https://pubchem.ncbi.nlm.nih.gov/compound/25023738,2.5,PI3K/Akt/mTOR,S6 Kinase,"BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40511.nd2.tif_merged.tif
2.3,F10,12,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Semaxanib,194413-58-6,238.28,https://pubchem.ncbi.nlm.nih.gov/compound/5329098,2.5,Protein Tyrosine Kinase,VEGFR,"Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM, 20-fold more selective for VEGFR than PDGFRβ, lack of activity against EGFR, InsR and FGFR. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40512.nd2.tif_merged.tif
2.3,G10,13,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Golvatinib,928037-13-2,633.69,https://pubchem.ncbi.nlm.nih.gov/compound/16118392,2.5,Protein Tyrosine Kinase,"c-Met,VEGFR","Golvatinib (E7050) is a dual c-Met and VEGFR-2 inhibitor with IC50 of 14 nM and 16 nM, does not inhibit bFGF-stimulated HUVEC growth (up to 1000 nM). Phase 1/2. ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40513.nd2.tif_merged.tif
2.3,G11,14,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,IMD 0354,978-62-1,383.67,https://pubchem.ncbi.nlm.nih.gov/compound/5081913,2.5,NF-κB,IκB/IKK,IMD-0354 is an IKKβ inhibitor and blocks IκBα phosphorylation in NF-κB pathway.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40514.nd2.tif_merged.tif
2.3,F11,15,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,WHI-P154,211555-04-3,376.2,https://pubchem.ncbi.nlm.nih.gov/compound/3795,2.5,JAK/STAT,"EGFR,JAK","WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40515.nd2.tif_merged.tif
2.3,E11,16,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GW5074,220904-83-6,520.94,https://pubchem.ncbi.nlm.nih.gov/compound/5924208,2.5,MAPK,Raf,"GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40516.nd2.tif_merged.tif
2.3,D11,17,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,IKK Inhibitor VII,873225-46-8,483.63,https://pubchem.ncbi.nlm.nih.gov/compound/9549298,2.5,NF-κB,IκB/IKK,"IKK Inhibitor VII (IKK-16) is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM in cell-free assays, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40517.nd2.tif_merged.tif
2.3,D12,18,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PF-562271,717907-75-0,507.49,https://pubchem.ncbi.nlm.nih.gov/compound/11713159,2.5,Angiogenesis,FAK,"PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40518.nd2.tif_merged.tif
2.3,E12,19,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GW441756,504433-23-2,275.3,https://pubchem.ncbi.nlm.nih.gov/compound/9943465,2.5,Protein Tyrosine Kinase,Trk receptor,"GW441756 is a potent, selective inhibitor of TrkA with IC50 of 2 nM, with very little activity to c-Raf1 and CDK2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40519.nd2.tif_merged.tif
2.3,F12,20,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Tyrphostin 9,10537-47-0,282.38,https://pubchem.ncbi.nlm.nih.gov/compound/5614,2.5,Protein Tyrosine Kinase,EGFR,"Tyrphostin 9 is firstly designed as an EGFR inhibitor with IC50 of 460 μM, but is also found to be more potent to PDGFR with IC50 of 0.5 μM.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40520.nd2.tif_merged.tif
2.3,G12,21,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,ZM 323881 HCl,193000-39-4,411.86,https://pubchem.ncbi.nlm.nih.gov/compound/22624897,2.5,Protein Tyrosine Kinase,VEGFR,"ZM 323881 is a potent and selective VEGFR2 inhibitor with IC50 of <2 nM, almost no activity on VEGFR1, PDGFRβ, FGFR1, EGFR and ErbB2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40521.nd2.tif_merged.tif
2.3,G13,22,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,ZM 306416,690206-97-4,333.74,https://pubchem.ncbi.nlm.nih.gov/compound/5329006,2.5,Protein Tyrosine Kinase,VEGFR,"ZM 306416 is a VEGFR (Flt and KDR) inhibitor for VEGFR1 with IC50 of 0.33 μM, but also found to inhibit EGFR with IC50 of <10 nM.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40522.nd2.tif_merged.tif
2.3,F13,23,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GNF-2,778270-11-4,374.32,https://pubchem.ncbi.nlm.nih.gov/compound/5311510,2.5,Angiogenesis,Bcr-Abl,"GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40523.nd2.tif_merged.tif
2.3,E13,24,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,S-Ruxolitinib,941685-37-6,306.37,https://pubchem.ncbi.nlm.nih.gov/compound/50878566,2.5,JAK/STAT,JAK,"S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40524.nd2.tif_merged.tif
2.3,D13,25,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PF-477736,952021-60-2,419.48,https://pubchem.ncbi.nlm.nih.gov/compound/135565545,2.5,Cell Cycle,Chk,"PF-477736 is a selective, potent and ATP-competitive Chk1 inhibitor with Ki of 0.49 nM in a cell-free assay and also inhibits VEGFR2, Aurora-A, FGFR3, Flt3, Fms (CSF1R), Ret and Yes. It shows ~100-fold selectivity for Chk1 than Chk2. Phase 1. ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40525.nd2.tif_merged.tif
2.3,D14,26,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Go 6983,133053-19-7,442.51,https://pubchem.ncbi.nlm.nih.gov/compound/3499,2.5,TGF-beta/Smad,PKC,"Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ and PKCδ with IC50 of 7 nM, 7 nM, 6 nM and 10 nM, respectively; less potent to PKCζ and inactive to PKCμ.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40526.nd2.tif_merged.tif
2.3,E14,27,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BAY 11-7082,19542-67-7,207.25,https://pubchem.ncbi.nlm.nih.gov/compound/5353431,2.5,NF-κB,"E2 conjugating,IκB/IKK","BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40527.nd2.tif_merged.tif
2.3,F14,28,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Icotinib,610798-31-7,391.42,https://pubchem.ncbi.nlm.nih.gov/compound/22024915,2.5,Protein Tyrosine Kinase,EGFR,"Icotinib is a potent and specific EGFR inhibitor with IC50 of 5 nM, including the EGFR, EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R).",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40528.nd2.tif_merged.tif
2.3,G14,29,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CHIR-99021 HCl,252917-06-9 (free base),501.8,https://pubchem.ncbi.nlm.nih.gov/compound/71295844,2.5,PI3K/Akt/mTOR,GSK-3,"CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM in cell-free assays; ability to distinguish between GSK-3 and its closest homologs Cdc2 and ERK2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40529.nd2.tif_merged.tif
2.3,G15,30,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,TDZD-8,327036-89-5,222.26,https://pubchem.ncbi.nlm.nih.gov/compound/4124851,2.5,PI3K/Akt/mTOR,GSK-3,"TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40530.nd2.tif_merged.tif
2.3,F15,31,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,TAK-715,303162-79-0,399.51,https://pubchem.ncbi.nlm.nih.gov/compound/9952773,2.5,MAPK,p38 MAPK,"TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40531.nd2.tif_merged.tif
2.3,E15,32,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Pazopanib,444731-52-6,437.52,https://pubchem.ncbi.nlm.nih.gov/compound/10113978,2.5,Protein Tyrosine Kinase,"c-Kit,PDGFR,VEGFR","Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40532.nd2.tif_merged.tif
2.3,D15,33,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Piceatannol,10083-24-6,244.24,https://pubchem.ncbi.nlm.nih.gov/compound/667639,2.5,Angiogenesis,Syk,"Piceatannol, a natural stilbene, is a selective Syk inhibitor and ~10-fold selectivity versus Lyn.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40533.nd2.tif_merged.tif
2.3,D16,34,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Schisandrin B,61281-37-6,400.46,https://pubchem.ncbi.nlm.nih.gov/compound/108130,2.5,PI3K/Akt/mTOR,ATM/ATR,Schisandrin B is the most abundant dibenzocyclooctadiene lignan present in the traditional Chinese medicinal herb Schisandra chinensis (Turcz.) Baill.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40534.nd2.tif_merged.tif
2.3,E16,35,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Cabozantinib malate,1140909-48-3,635.59,https://pubchem.ncbi.nlm.nih.gov/compound/25102846,2.5,Protein Tyrosine Kinase,"TAM Receptor,VEGFR","Cabozantinib malate (XL184) is the malate of Cabozantinib, a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40535.nd2.tif_merged.tif
2.3,F16,36,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,JNK-IN-8,1410880-22-6,507.59,https://pubchem.ncbi.nlm.nih.gov/compound/57340686,2.5,MAPK,JNK,"JNK-IN-8 is the first irreversible JNK inhibitor for JNK1, JNK2 and JNK4 with IC50 of 4.7 nM, 18.7 nM and 1 nM, >10-fold selectivity against MNK2, Fms and no inhibition to c-Kit, Met, PDGFRβin A375 cell line.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40536.nd2.tif_merged.tif
2.3,G16,37,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SC-514,354812-17-2,224.3,https://pubchem.ncbi.nlm.nih.gov/compound/2807869,2.5,NF-κB,IκB/IKK,"SC-514 is an orally active, ATP-competitive IKK-2 inhibitor with IC50 of 3-12 μM, blocks NF-κB-dependent gene expression, does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40537.nd2.tif_merged.tif
2.3,G17,38,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Tofacitinib Citrate,540737-29-9,504.49,https://pubchem.ncbi.nlm.nih.gov/compound/10174505,2.5,JAK/STAT,JAK,"Tofacitinib (CP-690550) Citrate is a novel inhibitor of JAK3 with IC50 of 1 nM in cell-free assays, 20- to 100-fold less potent against JAK2 and JAK1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40538.nd2.tif_merged.tif
2.3,F17,39,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Fingolimod HCl,162359-56-0,343.9,https://pubchem.ncbi.nlm.nih.gov/compound/107969,2.5,GPCR & G Protein,S1P Receptor,"Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40539.nd2.tif_merged.tif
2.3,E17,40,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,VX-702,745833-23-2,404.3,https://pubchem.ncbi.nlm.nih.gov/compound/10341154,2.5,MAPK,p38 MAPK,"VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40540.nd2.tif_merged.tif
2.3,D17,41,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,ALK-IN-1,1197958-12-5,529.01,https://pubchem.ncbi.nlm.nih.gov/compound/57390074,2.5,Protein Tyrosine Kinase,ALK,"ALK-IN-1 (AP26113) is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40541.nd2.tif_merged.tif
2.3,C17,42,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZD2932,883986-34-3,447.49,https://pubchem.ncbi.nlm.nih.gov/compound/11517980,2.5,Protein Tyrosine Kinase,"PDGFR,VEGFR,FLT3,c-Kit","AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40542.nd2.tif_merged.tif
2.3,C16,43,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Binimetinib,606143-89-9,441.23,https://pubchem.ncbi.nlm.nih.gov/compound/10288191,2.5,MAPK,MEK,"Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40543.nd2.tif_merged.tif
2.3,C15,44,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PP2,172889-27-9,301.77,https://pubchem.ncbi.nlm.nih.gov/compound/4878,2.5,Angiogenesis,Src,"PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40544.nd2.tif_merged.tif
2.3,C14,45,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,VS-5584,1246560-33-7,354.41,https://pubchem.ncbi.nlm.nih.gov/compound/46912230,2.5,PI3K/Akt/mTOR,PI3K,"VS-5584 (SB2343) is a potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40545.nd2.tif_merged.tif
2.3,C13,46,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CZC24832,1159824-67-5,364.4,https://pubchem.ncbi.nlm.nih.gov/compound/42623951,2.5,PI3K/Akt/mTOR,PI3K,"CZC24832 is the first selective PI3Kγ inhibitor with IC50 of 27 nM, with 10-fold selectivity over PI3Kβ and >100-fold selectivity over PI3Kα and PI3Kδ.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40546.nd2.tif_merged.tif
2.3,C12,47,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Duvelisib,1201438-56-3,416.86,https://pubchem.ncbi.nlm.nih.gov/compound/50905713,2.5,Angiogenesis,PI3K,"Duvelisib (IPI-145, INK1197) is a novel and selective PI3K δ/γ inhibitor with Ki and IC50 of 23 pM/243 pM and 1 nM/50 nM in cell-free assays, highly selective for PI3K δ/γ than other protein kinases. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40547.nd2.tif_merged.tif
2.3,C11,48,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,XL019,945755-56-6,444.53,https://pubchem.ncbi.nlm.nih.gov/compound/57990869,2.5,JAK/STAT,JAK,"XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, exhibiting >50-fold selectivity over JAK1, JAK3 and TYK2. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40548.nd2.tif_merged.tif
2.3,C10,49,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40549.nd2.tif_merged.tif
2.3,C9,50,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_2-3_40550.nd2.tif_merged.tif
3.1,C8,1,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PD168393,194423-15-9,369.22,https://pubchem.ncbi.nlm.nih.gov/compound/4708,2.5,Protein Tyrosine Kinase,EGFR,"PD168393 is an irreversible EGFR inhibitor with IC50 of 0.70 nM, irreversibly alkylate Cys-773; inactive against insulin, PDGFR, FGFR and PKC.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40501.nd2.tif_merged.tif
3.1,D8,2,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CX-6258 HCl,1353859-00-3,498.4,https://pubchem.ncbi.nlm.nih.gov/compound/72201040,2.5,JAK/STAT,Pim,"CX-6258 HCl is a potent, orally efficacious pan-Pim kinase inhibitor with IC50 of 5 nM, 25 nM and 16 nM for Pim1, Pim2, and Pim3, respectively.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40502.nd2.tif_merged.tif
3.1,E8,3,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZ20,1233339-22-4,412.51,https://pubchem.ncbi.nlm.nih.gov/compound/46244454,2.5,PI3K/Akt/mTOR,ATM/ATR,"AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40503.nd2.tif_merged.tif
3.1,F8,4,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CGI1746,910232-84-7,579.69,https://pubchem.ncbi.nlm.nih.gov/compound/24857323,2.5,Angiogenesis,BTK,CGI1746 is a potent and highly selective small-molecule inhibitor of the Btk with IC50 of 1.9 nM.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40504.nd2.tif_merged.tif
3.1,G8,5,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PP1,172889-26-8,281.36,https://pubchem.ncbi.nlm.nih.gov/compound/1400,2.5,Angiogenesis,Src,PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40505.nd2.tif_merged.tif
3.1,G9,6,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,LY2090314,603288-22-8,512.53,https://pubchem.ncbi.nlm.nih.gov/compound/10029385,2.5,PI3K/Akt/mTOR,GSK-3,LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. Phase 2.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40506.nd2.tif_merged.tif
3.1,F9,7,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,MK-8745,885325-71-3,431.91,https://pubchem.ncbi.nlm.nih.gov/compound/11676373,2.5,Cell Cycle,Aurora Kinase,"MK-8745 is a potent and selective Aurora A inhibitor with IC50 of 0.6 nM, more than 450-fold selectivity for Aurora A over Aurora B.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40507.nd2.tif_merged.tif
3.1,E9,8,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Tepotinib,1100598-32-0,492.57,https://pubchem.ncbi.nlm.nih.gov/compound/25171648,2.5,Protein Tyrosine Kinase,c-Met,"Tepotinib (EMD 1214063) is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40508.nd2.tif_merged.tif
3.1,D9,9,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,RN486,1242156-23-5,606.69,https://pubchem.ncbi.nlm.nih.gov/compound/46908026,2.5,Angiogenesis,BTK,RN486 is a potent and selective BTK inhibitor with IC50 of 4 nM.    ,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40509.nd2.tif_merged.tif
3.1,D10,10,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Ceritinib,1032900-25-6,558.14,https://pubchem.ncbi.nlm.nih.gov/compound/57379345,2.5,Protein Tyrosine Kinase,ALK,"Ceritinib (LDK378) is potent inhibitor against ALK with IC50 of 0.2 nM in cell-free assays, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40510.nd2.tif_merged.tif
3.1,E10,11,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GSK2334470,1227911-45-6,462.59,https://pubchem.ncbi.nlm.nih.gov/compound/46215815,2.5,PI3K/Akt/mTOR,PDK,"GSK2334470 is a novel PDK1 inhibitor with IC50 of ~10 nM in a cell-free assay, with no activity at other close related AGC-kinases.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40511.nd2.tif_merged.tif
3.1,F10,12,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Zotarolimus,221877-54-9,966.21,https://pubchem.ncbi.nlm.nih.gov/compound/9876378,2.5,PI3K/Akt/mTOR,mTOR,"Zotarolimus (ABT-578) is an analogue of rapamycin, and inhibits FKBP-12 binding with IC50 of 2.8 nM.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40512.nd2.tif_merged.tif
3.1,G10,13,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,IPA-3,42521-82-4,350.45,https://pubchem.ncbi.nlm.nih.gov/compound/521106,2.5,Cytoskeletal Signaling,PAK,"IPA-3 is a selective non-ATP competitive Pak1 inhibitor with IC50 of 2.5 μM in a cell-free assay, no inhibition to group II PAKs (PAKs 4-6).",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40513.nd2.tif_merged.tif
3.1,G11,14,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PF-3758309,898044-15-0,490.62,https://pubchem.ncbi.nlm.nih.gov/compound/25227462,2.5,Cytoskeletal Signaling,PAK,"PF-03758309 is a potent, ATP-competitive, pyrrolopyrazole inhibitor of PAK4  with IC50 of 1.3 nM.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40514.nd2.tif_merged.tif
3.1,F11,15,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,VE-822,1232416-25-9,463.55,https://pubchem.ncbi.nlm.nih.gov/compound/59472121,2.5,PI3K/Akt/mTOR,ATM/ATR,VE-822 is an ATR inhibitor with IC50 of 19 nM in HT29 cells.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40515.nd2.tif_merged.tif
3.1,E11,16,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZD1208,1204144-28-4,379.48,https://pubchem.ncbi.nlm.nih.gov/compound/58423153,2.5,JAK/STAT,Pim,"AZD1208 is a potent, and orally available Pim kinase inhibitor with IC50 of 0.4 nM, 5 nM, and 1.9 nM for Pim1, Pim2, and Pim3 in cell-free assays, respectively. Phase 1.         ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40516.nd2.tif_merged.tif
3.1,D11,17,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZD3463,1356962-20-3,448.95,https://pubchem.ncbi.nlm.nih.gov/compound/56599293,2.5,Protein Tyrosine Kinase,ALK,"AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75 nM, which also inhibits IGF1R with equivalent potency. ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40517.nd2.tif_merged.tif
3.1,D12,18,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,NU6027,220036-08-8,251.28,https://pubchem.ncbi.nlm.nih.gov/compound/398148,2.5,Cell Cycle,CDK,"NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40518.nd2.tif_merged.tif
3.1,E12,19,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,MLN2480,1096708-71-2,506.29,https://pubchem.ncbi.nlm.nih.gov/compound/25161177,2.5,MAPK,Raf,"MLN2480 is an oral, selective pan-Raf kinase inhibitor in chinical trials.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40519.nd2.tif_merged.tif
3.1,F12,20,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,TIC10 Analogue,41276-02-2,386.49,https://pubchem.ncbi.nlm.nih.gov/compound/336423,2.5,PI3K/Akt/mTOR,Akt,"TIC10 Analogue is an analogue of TIC10, which inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40520.nd2.tif_merged.tif
3.1,G12,21,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CGK 733,905973-89-9,555.84,https://pubchem.ncbi.nlm.nih.gov/compound/6605258,2.5,DNA Damage,ATM/ATR,CGK 733 is a potent and selective inhibitor of ATM/ATR with IC50 of ~200 nM.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40521.nd2.tif_merged.tif
3.1,G13,22,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZD1080,612487-72-6,334.37,https://pubchem.ncbi.nlm.nih.gov/compound/135564570,2.5,PI3K/Akt/mTOR,GSK-3,"AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with Ki of 6.9 nM and 31 nM, respectively, shows >14-fold selectivity against CDK2, CDK5, CDK1 and Erk2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40522.nd2.tif_merged.tif
3.1,F13,23,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,10058-F4,403811-55-2,249.35,https://pubchem.ncbi.nlm.nih.gov/compound/1271002,2.5,Cell Cycle,c-Myc,10058-F4 is a c-Myc inhibitor that specificallly inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40523.nd2.tif_merged.tif
3.1,E13,24,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Abemaciclib mesylate,1231930-82-7,602.7,https://pubchem.ncbi.nlm.nih.gov/compound/71576678,2.5,Cell Cycle,CDK,"Abemaciclib mesylate (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40524.nd2.tif_merged.tif
3.1,D13,25,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SSR128129E,848318-25-2,346.31,https://pubchem.ncbi.nlm.nih.gov/compound/68853159,2.5,Angiogenesis,FGFR,"SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40525.nd2.tif_merged.tif
3.1,D14,26,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CC-292,1202757-89-8,423.44,https://pubchem.ncbi.nlm.nih.gov/compound/59174488,2.5,Angiogenesis,BTK,"CC-292 (AVL-292) is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40526.nd2.tif_merged.tif
3.1,E14,27,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SKI II,312636-16-1,302.78,https://pubchem.ncbi.nlm.nih.gov/compound/753704,2.5,GPCR & G Protein,S1P Receptor,"SKI II is a highly selective and non ATP-competitive sphingosine kinase (SphK) inhibitor with IC50 of 0.5 μM, while exhibiting no inhibitory action on other kinases including PI3K, PKCα and ERK2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40527.nd2.tif_merged.tif
3.1,F14,28,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PF-543,1415562-82-1,465.6,https://pubchem.ncbi.nlm.nih.gov/compound/66577038,2.5,GPCR & G Protein,S1P Receptor,"PF-543, a novel sphingosine-competitive inhibitor of SphK1, inhibits SphK1 with IC50 and Ki of 2.0 nM and 3.6 nM, exhibits >100-fold selectivity over the SphK2 isoform.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40528.nd2.tif_merged.tif
3.1,G14,29,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GZD824 Dimesylate,1421783-64-3,724.77,https://pubchem.ncbi.nlm.nih.gov/compound/71519689,2.5,Angiogenesis,Bcr-Abl,"GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively. ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40529.nd2.tif_merged.tif
3.1,G15,30,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,RKI-1447,1342278-01-6,326.37,https://pubchem.ncbi.nlm.nih.gov/compound/60138149,2.5,Cell Cycle,ROCK,"RKI-1447 is a potent inhibitor of ROCK1 and ROCK2, with IC50 of 14.5 nM and 6.2 nM, respectively, has anti-invasive and antitumor activities.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40530.nd2.tif_merged.tif
3.1,F15,31,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BIO,667463-62-9,356.17,https://pubchem.ncbi.nlm.nih.gov/compound/448949,2.5,PI3K/Akt/mTOR,GSK-3,"BIO is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40531.nd2.tif_merged.tif
3.1,E15,32,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CNX-2006,1375465-09-0,545.53,https://pubchem.ncbi.nlm.nih.gov/compound/56968072,2.5,Protein Tyrosine Kinase,EGFR,"CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40532.nd2.tif_merged.tif
3.1,D15,33,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Bisindolylmaleimide I,133052-90-1,412.48,https://pubchem.ncbi.nlm.nih.gov/compound/2396,2.5,TGF-beta/Smad,PKC,"Bisindolylmaleimide I (GF109203X) is a potent PKC inhibitor with IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ in cell-free assays, respectively, showing more than 3000-fold selectivity for PKC as compared to EGFR, PDGFR and insulin receptor. ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40533.nd2.tif_merged.tif
3.1,D16,34,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GSK650394,890842-28-1,382.45,https://pubchem.ncbi.nlm.nih.gov/compound/25022668,2.5,Others,Others,"GSK650394 is a serum- and glucocorticoid-regulated kinase-1 inhibitor with IC50 of 62 nM and 103 nM for SGK1 and SGK2, respectively.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40534.nd2.tif_merged.tif
3.1,E16,35,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Skepinone-L,1221485-83-1,425.42,https://pubchem.ncbi.nlm.nih.gov/compound/45279963,2.5,MAPK,p38 MAPK,Skepinone-L is a selective p38α-MAPK inhibitor with IC50 of 5 nM.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40535.nd2.tif_merged.tif
3.1,F16,36,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Losmapimod,585543-15-3,383.46,https://pubchem.ncbi.nlm.nih.gov/compound/11552706,2.5,MAPK,p38 MAPK,"Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40536.nd2.tif_merged.tif
3.1,G16,37,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Ro3280,1062243-51-9,543.61,https://pubchem.ncbi.nlm.nih.gov/compound/25015677,2.5,Cell Cycle,PLK,"Ro3280 is a potent, highly selective inhibitor of  Polo-like kinase 1 (PLK1) with IC50 of 3 nM.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40537.nd2.tif_merged.tif
3.1,G17,38,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZD2858,486424-20-8,453.52,https://pubchem.ncbi.nlm.nih.gov/compound/10138980,2.5,PI3K/Akt/mTOR,GSK-3,"AZD2858 is a selective GSK-3 inhibitor with an IC50 of 68 nM, activating Wnt signaling, increases bone mass in rats.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40538.nd2.tif_merged.tif
3.1,F17,39,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CNX-774,1202759-32-7,499.5,https://pubchem.ncbi.nlm.nih.gov/compound/59174579,2.5,Angiogenesis,BTK,"CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor with IC50 of <1 nM.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40539.nd2.tif_merged.tif
3.1,E17,40,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PD173955,260415-63-2,443.35,https://pubchem.ncbi.nlm.nih.gov/compound/447077,2.5,Angiogenesis,Bcr-Abl,"PD173955 is a potent Bcr-Abl inhibitor with IC50 of 1-2 nM, also inhibiting Src activity with IC50 of 22 nM.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40540.nd2.tif_merged.tif
3.1,D17,41,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,FRAX597,1286739-19-2,558.1,https://pubchem.ncbi.nlm.nih.gov/compound/70934541,2.5,Cytoskeletal Signaling,PAK,"FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.   ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40541.nd2.tif_merged.tif
3.1,C17,42,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Rociletinib,1374640-70-6,555.55,https://pubchem.ncbi.nlm.nih.gov/compound/57335384,2.5,Protein Tyrosine Kinase,EGFR,"Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40542.nd2.tif_merged.tif
3.1,C16,43,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PFK15,4382-63-2,260.29,https://pubchem.ncbi.nlm.nih.gov/compound/25142799,2.5,Others,Others,PFK15 is a potent and selective 6-phosphofructo-2-kinase (PFKFB3) inhibitor with IC50 of 207 nM.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40543.nd2.tif_merged.tif
3.1,C15,44,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,TAK-632,1228591-30-7,554.52,https://pubchem.ncbi.nlm.nih.gov/compound/46209401,2.5,MAPK,Raf,"TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40544.nd2.tif_merged.tif
3.1,C14,45,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Osimertinib,1421373-65-0,499.61,https://pubchem.ncbi.nlm.nih.gov/compound/71496458,2.5,Protein Tyrosine Kinase,EGFR,"Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40545.nd2.tif_merged.tif
3.1,C13,46,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,WZ4003,1214265-58-3,496.99,https://pubchem.ncbi.nlm.nih.gov/compound/72200024,2.5,PI3K/Akt/mTOR,AMPK,"WZ4003 is a highly specific NUAK kinase inhibitor with IC50 of 20 nM and 100 nM for NUAK1 and NUAK2 in cell-base assays, respectively, without significant inhibition on 139 other kinases.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40546.nd2.tif_merged.tif
3.1,C12,47,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,HTH-01-015,1613724-42-7,468.55,https://pubchem.ncbi.nlm.nih.gov/compound/78357766,2.5,PI3K/Akt/mTOR,AMPK,"HTH-01-015 is a potent and selective NUAK1 inhibitor with IC50 of 100 nM, >100-fold selectivity over NUAK2.   ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40547.nd2.tif_merged.tif
3.1,C11,48,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,EHop-016,1380432-32-5,430.55,https://pubchem.ncbi.nlm.nih.gov/compound/51031035,2.5,Cell Cycle,Rho,"EHop-016 is a specific Rac GTPase inhibitor with IC50 of 1.1 μM for Rac1 in MDA-MB-435 and MDA-MB-231 cells, equally potent inhibition for Rac3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40548.nd2.tif_merged.tif
3.1,C10,49,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40549.nd2.tif_merged.tif
3.1,C9,50,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-1_40550.nd2.tif_merged.tif
3.2,C8,1,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,TG003,300801-52-9,249.33,https://pubchem.ncbi.nlm.nih.gov/compound/1893668,2.5,Cell Cycle,CDK,"TG003 is a potent and ATP-competitive Cdc2-like kinase (Clk) inhibitor with IC50 of 20 nM, 200 nM, and 15 nM for Clk1, Clk2, and Clk4, respectively. No inhibitory effect on Clk3, SRPK1, SRPK2, or PKC.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40501.nd2.tif_merged.tif
3.2,D8,2,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,ERK5-IN-1,1435488-37-1,638.81,https://pubchem.ncbi.nlm.nih.gov/compound/71604307,2.5,MAPK,ERK,"ERK5-IN-1 is a potent, and selective ERK5 inhibitor with IC50 of 162 nM.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40502.nd2.tif_merged.tif
3.2,E8,3,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,URMC-099,1229582-33-5,421.54,https://pubchem.ncbi.nlm.nih.gov/compound/54764565,2.5,Others,LRRK2,"URMC-099 is an orally bioavailable, brain penetrant mixed lineage kinase (MLK) inhibitor with IC50 of 19 nM, 42 nM, 14 nM, and 150 nM, for MLK1, MLK2, MLK3, and DLK, respectively, and also inhibits LRRK2 activity with IC50 of 11 nM.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40503.nd2.tif_merged.tif
3.2,F8,4,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Bay 11-7085,196309-76-9,249.33,https://pubchem.ncbi.nlm.nih.gov/compound/5353432,2.5,NF-κB,IκB/IKK,BAY 11-7085 is an irreversible inhibitor of TNFα-induced IκBα phosphorylation with IC50 of 10 μM.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40504.nd2.tif_merged.tif
3.2,G8,5,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,HS-173,1276110-06-5,422.46,https://pubchem.ncbi.nlm.nih.gov/compound/52936849,2.5,PI3K/Akt/mTOR,PI3K,HS-173 is a potent PI3Kα inhibitor with IC50 of 0.8 nM.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40505.nd2.tif_merged.tif
3.2,G9,6,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GNE-0877,1374828-69-9,339.32,https://pubchem.ncbi.nlm.nih.gov/compound/69093374,2.5,Autophagy,LRRK2,GNE-0877 is a highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor with Ki of 0.7 nM.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40506.nd2.tif_merged.tif
3.2,F9,7,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GNE-9605,1536200-31-3,449.83,https://pubchem.ncbi.nlm.nih.gov/compound/76328936,2.5,Autophagy,LRRK2,"GNE-9605 is a highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor with Ki and IC50 of 2 nM and 19 nM, respectively.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40507.nd2.tif_merged.tif
3.2,E9,8,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Sorafenib,284461-73-0,464.82,https://pubchem.ncbi.nlm.nih.gov/compound/216239,2.5,MAPK,Raf,"Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40508.nd2.tif_merged.tif
3.2,D9,9,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,KN-62,127191-97-3,721.84,https://pubchem.ncbi.nlm.nih.gov/compound/5312126,2.5,Others,CaMK,KN-62 is a potent and specific inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII) with Ki of 0.9 μM.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40509.nd2.tif_merged.tif
3.2,D10,10,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,KN-93 Phosphate,1188890-41-6,599.03,https://pubchem.ncbi.nlm.nih.gov/compound/16760530,2.5,Others,CaMK,"KN-93 Phosphate is a potent and specific inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII) with Ki of 0.37 μM, no remarkable inhibitory effects on APK, PKC, MLCK or Ca2+-PDE activities.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40510.nd2.tif_merged.tif
3.2,E10,11,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AR-A014418,487021-52-3,308.31,https://pubchem.ncbi.nlm.nih.gov/compound/448014,2.5,PI3K/Akt/mTOR,GSK-3,"AR-A014418 is an ATP-competitive, and selective GSK3β inhibitor with IC50 and Ki of 104 nM and 38 nM in cell-free assays, without significant inhibition on 26 other kinases tested.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40511.nd2.tif_merged.tif
3.2,F10,12,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,LDC000067,1073485-20-7,370.43,https://pubchem.ncbi.nlm.nih.gov/compound/25104564,2.5,Cell Cycle,CDK,"LDC000067 is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40512.nd2.tif_merged.tif
3.2,G10,13,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Uprosertib,1047634-65-0,429.25,https://pubchem.ncbi.nlm.nih.gov/compound/51042438,2.5,PI3K/Akt/mTOR,Akt,"Uprosertib (GSK2141795) is a selective, ATP-competitive, and orally bioavailable Akt inhibitor with IC50 of 180 nM, 328 nM, and 38 nM for Akt 1, 2 and 3, respectively. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40513.nd2.tif_merged.tif
3.2,G11,14,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DDR1-IN-1,1449685-96-4,552.59,https://pubchem.ncbi.nlm.nih.gov/compound/72836888,2.5,Others,Others,"DDR1-IN-1 is a potent and selective discoidin domain receptor 1 (DDR1) receptor tyrosine kinase inhibitor with IC50 of 105 nM, about 3-fold selectivity over DDR2.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40514.nd2.tif_merged.tif
3.2,F11,15,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,JNK Inhibitor IX,312917-14-9,332.42,https://pubchem.ncbi.nlm.nih.gov/compound/766949,2.5,MAPK,JNK,"JNK inhibitor IX is a selective and potent JNK inhibitor with pIC50 of 6.5 and 6.7 for JNK2 and JNK3, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40515.nd2.tif_merged.tif
3.2,E11,16,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,XMD8-92,1234480-50-2,474.55,https://pubchem.ncbi.nlm.nih.gov/compound/46843772,2.5,MAPK,ERK,XMD8-92 is a potent and selective BMK1/ERK5 inhibitor with Kd of 80 nM.  ,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40516.nd2.tif_merged.tif
3.2,D11,17,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GNF-5,778277-15-9,418.37,https://pubchem.ncbi.nlm.nih.gov/compound/44129660,2.5,Angiogenesis,Bcr-Abl,GNF-5 is a selective and allosteric Bcr-Abl inhibitor with IC50 of 220 nM. ,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40517.nd2.tif_merged.tif
3.2,D12,18,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GNE-7915,1351761-44-8,443.4,https://pubchem.ncbi.nlm.nih.gov/compound/58539171,2.5,Autophagy,LRRK2,"GNE-7915 is a highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) inhibitor,  with IC50 and Ki of 9 nM and 1 nM, respectively.   ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40518.nd2.tif_merged.tif
3.2,E12,19,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Decernotinib,944842-54-0,392.38,https://pubchem.ncbi.nlm.nih.gov/compound/59422203,2.5,JAK/STAT,JAK,"Decernotinib (VX-509) is a potent and selective JAK3 inhibitor with Ki of 2.5 nM, >4-fold selectivity over JAK1, JAK2, and TYK2, respectively. Phase 2/3.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40519.nd2.tif_merged.tif
3.2,F12,20,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Vacquinol-1,5428-80-8 (free base),425.78,https://pubchem.ncbi.nlm.nih.gov/compound/129896712,2.5,MAPK,JNK,"Vacquinol-1 is an MKK4 activator, which rapidly and selectively induces glioma cell death.   ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40520.nd2.tif_merged.tif
3.2,G12,21,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,G-749,1457983-28-6,521.41,https://pubchem.ncbi.nlm.nih.gov/compound/78357765,2.5,Angiogenesis,FLT3,"G-749 is a novel and potent FLT3 inhibitor with IC50 of 0.4 nM, 0.6 nM and 1 nM for FLT3 (WT), FLT3 (D835Y), and Mer, respectively, showing lower potency against other tyrosine kinases.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40521.nd2.tif_merged.tif
3.2,G13,22,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AT13148,1056901-62-2,313.78,https://pubchem.ncbi.nlm.nih.gov/compound/24905401,2.5,PI3K/Akt/mTOR,"Akt,S6 Kinase,ROCK,PKA","AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40522.nd2.tif_merged.tif
3.2,F13,23,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,WH-4-023,837422-57-8,568.67,https://pubchem.ncbi.nlm.nih.gov/compound/11844351,2.5,Angiogenesis,Src,"WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.     ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40523.nd2.tif_merged.tif
3.2,E13,24,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,IM-12,1129669-05-1,377.41,https://pubchem.ncbi.nlm.nih.gov/compound/25209788,2.5,PI3K/Akt/mTOR,GSK-3,"IM-12 is a selective GSK-3β inhibitor with IC50 of 53 nM, and also enhances canonical Wnt signalling.   ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40524.nd2.tif_merged.tif
3.2,D13,25,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Anacardic Acid,16611-84-0,348.52,https://pubchem.ncbi.nlm.nih.gov/compound/167551,2.5,Epigenetics,Histone Acetyltransferase,"Anacardic Acid is a potent inhibitor of p300 and p300/CBP-associated factor histone acetyltranferases, which also has antibacterial activity, antimicrobial activity,  prostaglandin synthase inhibition, and tyrosinase and lipoxygenase inhibition.   ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40525.nd2.tif_merged.tif
3.2,D14,26,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Filgotinib,1206161-97-8,425.5,https://pubchem.ncbi.nlm.nih.gov/compound/49831257,2.5,JAK/STAT,JAK,"Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. Phase 2.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40526.nd2.tif_merged.tif
3.2,E14,27,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,LDN-214117,1627503-67-6,419.52,https://pubchem.ncbi.nlm.nih.gov/compound/91754554,2.5,TGF-beta/Smad,TGF-beta/Smad,LDN-214117 is a potent and selective BMP type I receptor kinase ALK2 inhibitor with IC50 of 24 nM.  ,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40527.nd2.tif_merged.tif
3.2,F14,28,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SU9516,377090-84-1,241.25,https://pubchem.ncbi.nlm.nih.gov/compound/5289419,2.5,Cell Cycle,CDK,"SU9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40528.nd2.tif_merged.tif
3.2,G14,29,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,D4476,301836-43-1,398.41,https://pubchem.ncbi.nlm.nih.gov/compound/6419753,2.5,Metabolism,Casein Kinase,"D4476 is a potent, selective, and cell-permeant CK1 (casein kinase 1) inhibitor with IC50 of 200 nM and 300 nM in a cell-free assay for CK1 from Schizosaccharomyces pombe and CK1δ, respectively. Also acts as an ALK5 inhibitor with IC50 of 500 nM.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40529.nd2.tif_merged.tif
3.2,G15,30,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PF-431396,717906-29-1,506.5,https://pubchem.ncbi.nlm.nih.gov/compound/11598628,2.5,Angiogenesis,FAK,"PF-431396 is a dual PYK2/FAK inhibitor with IC50 of 11 nM and 2 nM, respectively.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40530.nd2.tif_merged.tif
3.2,F15,31,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GSK2578215A,1285515-21-0,399.42,https://pubchem.ncbi.nlm.nih.gov/compound/68107965,2.5,Autophagy,LRRK2,"GSK2578215A is a potent and selective LRRK2 kinase inhibitor with IC50 of 8.9 nM and 10.9 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40531.nd2.tif_merged.tif
3.2,E15,32,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZD6738,1352226-88-0,412.51,https://pubchem.ncbi.nlm.nih.gov/compound/54761306,2.5,PI3K/Akt/mTOR,ATM/ATR,"AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40532.nd2.tif_merged.tif
3.2,D15,33,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,VX-11e,896720-20-0,500.35,https://pubchem.ncbi.nlm.nih.gov/compound/11634725,2.5,MAPK,ERK,"VX-11e is a potent, selective, and orally bioavailable ERK2 inhibitor with Ki of <2 nM, over 200-fold selective over other kinases tested.   ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40533.nd2.tif_merged.tif
3.2,D16,34,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,FIIN-2,1633044-56-0,634.73,https://pubchem.ncbi.nlm.nih.gov/compound/91825767,2.5,Protein Tyrosine Kinase,FGFR,"FIIN-2 is an irreversible, pan-FGFR inhibitor with IC50 of 3.09 nM, 4.3 nM, 27 nM and 45.3 nM for FGFR1/2/3/4, respectively.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40534.nd2.tif_merged.tif
3.2,E16,35,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Bikinin,188011-69-0,273.08,https://pubchem.ncbi.nlm.nih.gov/compound/647833,2.5,PI3K/Akt/mTOR,GSK-3,"Bikinin is an ATP-competitive Arabidopsis GSK-3 inhibitor, and acts as a strong activator of brassinosteroid (BR) signaling.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40535.nd2.tif_merged.tif
3.2,F16,36,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BLZ945,953769-46-5,398.48,https://pubchem.ncbi.nlm.nih.gov/compound/46184986,2.5,Protein Tyrosine Kinase,CSF-1R,"BLZ945 is an orally active, potent and selective CSF-1R inhibitor with IC50 of 1 nM, >1000-fold selective against its closest receptor tyrosine kinase homologs.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40536.nd2.tif_merged.tif
3.2,G16,37,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,LFM-A13,244240-24-2,360,https://pubchem.ncbi.nlm.nih.gov/compound/54676905,2.5,Angiogenesis,BTK,"LFM-A13 is a specific Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 2.5 μM, >100-fold selectivity over other protein kinases including JAK1, JAK2, HCK, EGFR,and IRK.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40537.nd2.tif_merged.tif
3.2,G17,38,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SB239063,193551-21-2,368.4,https://pubchem.ncbi.nlm.nih.gov/compound/5166,2.5,MAPK,p38 MAPK,"SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.   ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40538.nd2.tif_merged.tif
3.2,F17,39,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,ANA-12,219766-25-3,407.49,https://pubchem.ncbi.nlm.nih.gov/compound/2799722,2.5,Protein Tyrosine Kinase,Trk receptor,"ANA-12 is a selective TrkB antagonist with Kd of 10 nM and 12 μM for the high and low affinity sites, respectively.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40539.nd2.tif_merged.tif
3.2,E17,40,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Ro-3306,872573-93-8,351.45,https://pubchem.ncbi.nlm.nih.gov/compound/135400873,2.5,Cell Cycle,CDK,"Ro-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40540.nd2.tif_merged.tif
3.2,D17,41,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Pluripotin,839707-37-8,550.53,https://pubchem.ncbi.nlm.nih.gov/compound/12003241,2.5,MAPK,ERK,"Pluripotin (SC1) is a dual inhibitor of extracellular signal-regulated kinase 1 (ERK1, MAPK3) and RasGAP. Maintains embryonic stem cell (ESC) self-renewal.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40541.nd2.tif_merged.tif
3.2,C17,42,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SU6656,330161-87-0,371.45,https://pubchem.ncbi.nlm.nih.gov/compound/5312137,2.5,Angiogenesis,Src,"SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40542.nd2.tif_merged.tif
3.2,C16,43,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Akti-1/2,612847-09-3,551.64,https://pubchem.ncbi.nlm.nih.gov/compound/135398501,2.5,PI3K/Akt/mTOR,Akt,"Akti-1/2 is a highly selective Akt1/Akt2 inhibitor with IC50 of 58 nM/210 nM, respectively, about 36-fold selectivity for Akt1 over Akt3.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40543.nd2.tif_merged.tif
3.2,C15,44,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Purvalanol A,212844-53-6,388.89,https://pubchem.ncbi.nlm.nih.gov/compound/456214,2.5,Cell Cycle,CDK,"Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40544.nd2.tif_merged.tif
3.2,C14,45,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AMG319,1608125-21-8,385.4,https://pubchem.ncbi.nlm.nih.gov/compound/68947304,2.5,PI3K/Akt/mTOR,PI3K,"AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40545.nd2.tif_merged.tif
3.2,C13,46,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SGI-7079,1239875-86-5,455.53,https://pubchem.ncbi.nlm.nih.gov/compound/46870258,2.5,Protein Tyrosine Kinase,VEGFR,"SGI-7079 ,a novel selective Axl inhibitor, inhibits tumor growth in a dose dependent manner and is a potential therapeutic target for overcoming EGFR inhibitor resistance.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40546.nd2.tif_merged.tif
3.2,C12,47,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Ulixertinib,869886-67-9,433.33,https://pubchem.ncbi.nlm.nih.gov/compound/11719003,2.5,MAPK,ERK,"Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40547.nd2.tif_merged.tif
3.2,C11,48,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,LJH685,1627710-50-2,381.42,https://pubchem.ncbi.nlm.nih.gov/compound/73010393,2.5,PI3K/Akt/mTOR,S6 Kinase,"LJH685 is a potent pan-RSK inhibitor with IC50 of 6 nM, 5 nM and 4 nM for RSK1, RSK2, and RSK3, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40548.nd2.tif_merged.tif
3.2,C10,49,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40549.nd2.tif_merged.tif
3.2,C9,50,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-2_40550.nd2.tif_merged.tif
3.3,C8,1,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,LJI308,1627709-94-7,368.38,https://pubchem.ncbi.nlm.nih.gov/compound/118704762,2.5,PI3K/Akt/mTOR,S6 Kinase,"LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40501.nd2.tif_merged.tif
3.3,D8,2,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,ONO-4059 analogue,1351635-67-0,456.5,https://pubchem.ncbi.nlm.nih.gov/compound/89455219,2.5,Angiogenesis,BTK,"ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40502.nd2.tif_merged.tif
3.3,E8,3,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CC-223,1228013-30-6,397.47,https://pubchem.ncbi.nlm.nih.gov/compound/58298316,2.5,PI3K/Akt/mTOR,mTOR,"CC-223 is a potent, selective, and orally bioavailable mTOR inhibitor with IC50 of 16 nM, >200-fold selectivity over the related PI3K-α. Phase 1/2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40503.nd2.tif_merged.tif
3.3,F8,4,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GSK621,1346607-05-3,489.91,https://pubchem.ncbi.nlm.nih.gov/compound/54577153,2.5,PI3K/Akt/mTOR,AMPK,GSK621 is a specific and potent AMPK activator.  ,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40504.nd2.tif_merged.tif
3.3,G8,5,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DASA-58,1203494-49-8,453.53,https://pubchem.ncbi.nlm.nih.gov/compound/44543605,2.5,Others,Others,DASA-58 is a specific and potent Pyruvate kinase M2 (PKM2) activator.  ,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40505.nd2.tif_merged.tif
3.3,G9,6,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GSK2292767,1254036-66-2,512.58,https://pubchem.ncbi.nlm.nih.gov/compound/49783923,2.5,PI3K/Akt/mTOR,PI3K,GSK2292767 is a potent and selective PI3Kδ inhibitor.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40506.nd2.tif_merged.tif
3.3,F9,7,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,ETC-1002,738606-46-7,344.49,https://pubchem.ncbi.nlm.nih.gov/compound/10472693,2.5,PI3K/Akt/mTOR,AMPK,"ETC-1002,also known as Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.ETC-1002 is an activator of hepatic AMP-activated protein kinase (AMPK). It has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40507.nd2.tif_merged.tif
3.3,E9,8,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PLX7904,1393465-84-3,512.53,https://pubchem.ncbi.nlm.nih.gov/compound/90116945,2.5,MAPK,Raf,"PLX7904, also known as PB04, is a potent and selective paradox-breaker RAF inhibitor. It is able to efficiently inhibit activation of ERK1/2 in mutant BRAF melanoma cells but does not hyperactivate ERK1/2 in mutant RAS-expressing cells.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40508.nd2.tif_merged.tif
3.3,D9,9,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZD3759,1626387-80-1,459.9,https://pubchem.ncbi.nlm.nih.gov/compound/78209992,2.5,Protein Tyrosine Kinase,EGFR,"AZD3759 is a potent, oral active, CNS-penetrant EGFR inhibitor with IC50 of 0.3 nM, 0.2 nM, and 0.2 nM for EGFR (WT), EGFR (L858R), and EGFR (exon 19Del), respectively. Phase 1.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40509.nd2.tif_merged.tif
3.3,D10,10,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,VPS34-IN1,1383716-33-3,425.91,https://pubchem.ncbi.nlm.nih.gov/compound/57404276,2.5,PI3K/Akt/mTOR,PI3K,"Vps34-IN1 is a potent and highly selective Vps34 inhibitor with IC50 of 25 nM invitro,which does not significantly inhibit the isoforms of class I as well as class II PI3Ks.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40510.nd2.tif_merged.tif
3.3,E10,11,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Entrectinib,1108743-60-7,560.64,https://pubchem.ncbi.nlm.nih.gov/compound/25141092,2.5,Protein Tyrosine Kinase,"Trk receptor,ALK","Entrectinib (RXDX-101) is an orally bioavailable pan-TrkA/B/C, ROS1 and ALK inhibitor with IC50 ranging between 0.1 and 1.7 nM. Phase 2.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40511.nd2.tif_merged.tif
3.3,F10,12,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GSK2636771,1372540-25-4,433.42,https://pubchem.ncbi.nlm.nih.gov/compound/56949517,2.5,PI3K/Akt/mTOR,PI3K,"GSK2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines. Phase 1/2a.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40512.nd2.tif_merged.tif
3.3,G10,13,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PQ 401,196868-63-0,341.79,https://pubchem.ncbi.nlm.nih.gov/compound/9549305,2.5,Protein Tyrosine Kinase,IGF-1R,PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40513.nd2.tif_merged.tif
3.3,G11,14,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,ZM 39923 HCl,1021868-92-7,367.91,https://pubchem.ncbi.nlm.nih.gov/compound/176406,2.5,JAK/STAT,JAK,"ZM 39923 HCl is an JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to be sensitive to transglutaminase.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40514.nd2.tif_merged.tif
3.3,F11,15,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,SMI-4a,438190-29-5,273.23,https://pubchem.ncbi.nlm.nih.gov/compound/1361334,2.5,JAK/STAT,Pim,"SMI-4a is a potent inhibitor of Pim1 with IC50 of 17 nM, modestly potent to Pim-2, does not significantly inhibit any other serine/threonine- or tyrosine-kinases.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40515.nd2.tif_merged.tif
3.3,E11,16,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,VE-821,1232410-49-9,368.41,https://pubchem.ncbi.nlm.nih.gov/compound/51000408,2.5,DNA Damage,ATM/ATR,"VE-821 is a potent and selective ATP competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM in cell-free assays, shows inhibition of H2AX phosphorylation, minimal activity against PIKKs ATM, DNA-PK, mTOR and PI3Kγ.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40516.nd2.tif_merged.tif
3.3,D11,17,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AG-18,118409-57-7,186.17,https://pubchem.ncbi.nlm.nih.gov/compound/2052,2.5,Protein Tyrosine Kinase,EGFR,AG-18 inhibits EGFR with IC50 of 35 μM.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40517.nd2.tif_merged.tif
3.3,D12,18,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,CEP-32496,1188910-76-0,517.46,https://pubchem.ncbi.nlm.nih.gov/compound/56846693,2.5,MAPK,"CSF-1R,Raf","CEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2. Phase 1/2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40518.nd2.tif_merged.tif
3.3,E12,19,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AZD5363,1143532-39-1,428.92,https://pubchem.ncbi.nlm.nih.gov/compound/25227436,2.5,PI3K/Akt/mTOR,Akt,"AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40519.nd2.tif_merged.tif
3.3,F12,20,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,TCS 359,301305-73-7,360.43,https://pubchem.ncbi.nlm.nih.gov/compound/1048845,2.5,Angiogenesis,FLT3,TCS 359 is a potent FLT3 inhibitor with IC50 of 42 nM.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40520.nd2.tif_merged.tif
3.3,G12,21,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Tyrphostin AG 1296,146535-11-7,266.29,https://pubchem.ncbi.nlm.nih.gov/compound/2049,2.5,Protein Tyrosine Kinase,"c-Kit,FGFR,PDGFR","Tyrphostin AG 1296 is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40521.nd2.tif_merged.tif
3.3,G13,22,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,NSC 23766,1177865-17-6,530.96,https://pubchem.ncbi.nlm.nih.gov/compound/16759159,2.5,Cell Cycle,Rho,"NSC 23766 is an inhibitor of Rac GTPase targeting Rac activation by guanine nucleotide exchange factors (GEFs) with IC50 of ~50 μM in a cell-free assay; does not inhibit the closely related  targets, Cdc42 or RhoA.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40522.nd2.tif_merged.tif
3.3,F13,23,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,PRT062607 HCl,"1370261-97-4,1370261-96-3(free base)",429.91,https://pubchem.ncbi.nlm.nih.gov/compound/56948527,2.5,Angiogenesis,Syk,"PRT062607 (P505-15, BIIB057) HCl is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, Lyn, FAK, Pyk2 and Zap70.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40523.nd2.tif_merged.tif
3.3,E13,24,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Butein,487-52-5,272.25,https://pubchem.ncbi.nlm.nih.gov/compound/5281222,2.5,Protein Tyrosine Kinase,EGFR,"Butein, a plant polyphenol isolated from <i>Rhus verniciflua</i>, is able to inhibit the activation of protein tyrosine kinase, NF-κB and STAT3, also inhibits EGFR.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40524.nd2.tif_merged.tif
3.3,D13,25,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,GDC-0349,1207360-89-1,452.55,https://pubchem.ncbi.nlm.nih.gov/compound/59239165,2.5,PI3K/Akt/mTOR,mTOR,"GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40525.nd2.tif_merged.tif
3.3,D14,26,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Cobimetinib,934660-93-2,531.31,https://pubchem.ncbi.nlm.nih.gov/compound/16222096,2.5,MAPK,MEK,"Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM. Phase 3.  ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40526.nd2.tif_merged.tif
3.3,E14,27,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BMS-345541,445430-58-0,255.32,https://pubchem.ncbi.nlm.nih.gov/compound/9813758,2.5,NF-κB,IκB/IKK,"BMS-345541 is a highly selective inhibitor of the catalytic subunits of IKK-2 and IKK-1 with IC50 of 0.3 μM and 4 μM in cell-free assays, respectively.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40527.nd2.tif_merged.tif
3.3,F14,28,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,ETP-46464,1345675-02-6,470.52,https://pubchem.ncbi.nlm.nih.gov/compound/72199292,2.5,PI3K/Akt/mTOR,"ATM/ATR,mTOR",ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40528.nd2.tif_merged.tif
3.3,G14,29,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,ASP3026,1097917-15-1,580.74,https://pubchem.ncbi.nlm.nih.gov/compound/25134326,2.5,Protein Tyrosine Kinase,ALK,ASP3026 is a novel and selective inhibitor for ALK  with IC50 of 3.5 nM. Phase 1.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40529.nd2.tif_merged.tif
3.3,G15,30,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Pacritinib,937272-79-2,472.58,https://pubchem.ncbi.nlm.nih.gov/compound/46216796,2.5,JAK/STAT,"FLT3,JAK","Pacritinib (SB1518) is a potent and selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3) with IC50s of 23 and 22 nM in cell-free assays, respectively. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40530.nd2.tif_merged.tif
3.3,F15,31,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,P276-00,920113-03-7,438.3,https://pubchem.ncbi.nlm.nih.gov/compound/23643975,2.5,Cell Cycle,CDK,"P276-00 is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. Phase 2/3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40531.nd2.tif_merged.tif
3.3,E15,32,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BMS-582949,623152-17-0,406.48,https://pubchem.ncbi.nlm.nih.gov/compound/10409068,2.5,MAPK,p38 MAPK,"BMS-582949 is a potent and selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor with IC50 of 13nM,inhibiting both p38 kinase activity and activation of p38.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40532.nd2.tif_merged.tif
3.3,D15,33,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,AMG 337,1173699-31-4,463.46,https://pubchem.ncbi.nlm.nih.gov/compound/44181686,2.5,Protein Tyrosine Kinase,c-Met,"AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the MET receptor.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40533.nd2.tif_merged.tif
3.3,D16,34,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Oclacitinib,1640292-55-2,453.51,https://pubchem.ncbi.nlm.nih.gov/compound/44631937,2.5,JAK/STAT,JAK,"Oclacitinib is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ranging from 36 to 249 nM, which did not inhibit a panel of 38 non-JAK kinases.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40534.nd2.tif_merged.tif
3.3,E16,35,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,BI-78D3,883065-90-5,379.37,https://pubchem.ncbi.nlm.nih.gov/compound/2747117,2.5,MAPK,JNK,BI-78D3 is a competitive JNK inhibitor with IC50 of 280nM that displays > 100 fold selectivity over p38α and no activity at mTOR and PI-3K.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40535.nd2.tif_merged.tif
3.3,F16,36,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Olmutinib,1353550-13-6,486.59,https://pubchem.ncbi.nlm.nih.gov/compound/54758501,2.5,Protein Tyrosine Kinase,EGFR,"Olmutinib (HM61713, BI 1482694) is a novel third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI). Also a potent inhibitor of Bruton's tyrosine kinase.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40536.nd2.tif_merged.tif
3.3,G16,37,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,"7,8-Dihydroxyflavone",38183-03-8,254.24,https://pubchem.ncbi.nlm.nih.gov/compound/1880,2.5,Protein Tyrosine Kinase,Trk receptor,"7,8-Dihydroxyflavone acts as a potent and selective small-molecule agonist of the TrkB receptor (Kd ≈ 320 nM), the main signaling receptor of brain-derived neurotrophic factor (BDNF).",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40537.nd2.tif_merged.tif
3.3,G17,38,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,LY3023414,1386874-06-1,406.48,https://pubchem.ncbi.nlm.nih.gov/compound/57519748,2.5,PI3K/Akt/mTOR,Akt,"LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40538.nd2.tif_merged.tif
3.3,F17,39,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Perifosine,157716-52-4,461.66,https://pubchem.ncbi.nlm.nih.gov/compound/148177,2.5,PI3K/Akt/mTOR,Akt,"Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40539.nd2.tif_merged.tif
3.3,E17,40,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Palbociclib HCl,"827022-32-2, 571190-30-2 (free base)",483.99,https://pubchem.ncbi.nlm.nih.gov/compound/11431660,2.5,Others,CDK,"Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40540.nd2.tif_merged.tif
3.3,D17,41,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,LY2228820,862507-23-1,612.74,https://pubchem.ncbi.nlm.nih.gov/compound/11570805,2.5,MAPK,p38 MAPK,"LY2228820 is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40541.nd2.tif_merged.tif
3.3,C17,42,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Miltefosine,58066-85-6,407.57,https://pubchem.ncbi.nlm.nih.gov/compound/3599,2.5,PI3K/Akt/mTOR,Akt,"Miltefosine inhibits PI3K/Akt activity with ED50 of 17.2 μM and 8.1 μM in carcinoma cell lines A431 and HeLa, first oral drug for Visceral leishmaniasis, effective against both promastigotes and amastigotes.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40542.nd2.tif_merged.tif
3.3,C16,43,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Chloroquine Phosphate,50-63-5,515.86,https://pubchem.ncbi.nlm.nih.gov/compound/64927,2.5,PI3K/Akt/mTOR,"ATM/ATR,Autophagy","Chloroquine phosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator. ",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40543.nd2.tif_merged.tif
3.3,C15,44,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,Dorsomorphin 2HCl,1219168-18-9,472.41,https://pubchem.ncbi.nlm.nih.gov/compound/49761481,2.5,PI3K/Akt/mTOR,AMPK,"Dorsomorphin 2HCl is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type Ⅰ BMP receptor activity.",,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40544.nd2.tif_merged.tif
3.3,C14,45,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,APTSTAT3-9R,NA,4947.51,https://pubchem.ncbi.nlm.nih.gov/compound/131709226,2.5,JAK/STAT,STAT,APTSTAT3-9R is a specific STAT3-binding peptide with addition of a cell-penetrating motif. The treatment of APTSTAT3-9R in various types of cancer cells blocks STAT3 phosphorylation and reduces expression of STAT targets.,,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40545.nd2.tif_merged.tif
3.3,C13,46,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,None,,,,2.5,,,,untreated control,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40546.nd2.tif_merged.tif
3.3,C12,47,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,None,,,,2.5,,,,untreated control,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40547.nd2.tif_merged.tif
3.3,C11,48,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,None,,,,2.5,,,,untreated control,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40548.nd2.tif_merged.tif
3.3,C10,49,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40549.nd2.tif_merged.tif
3.3,C9,50,Mus musculus,NCBITaxon,10090,Primary mouse keratinocytes,DMSO,,,,2.5,,,,vehicle control,405:ErkKTR-BFP; 561:H2B-RFP,plate_3-3_40550.nd2.tif_merged.tif